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Piperazine derivatives have been identified as new antidiabetic compounds. Structure-activity
relationship studies in a series of 1-benzyl-4-alkyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines
resulted in the identification of 1-methyl-4-(2′,4′-dichlorobenzyl)-2-(4′,5′-dihydro-1′H-imidazol-
2′-yl)piperazine, PMS 812 (S-21663), as a highly potent antidiabetic agent on a rat model of
diabetes, mediated by an important increase of insulin secretion independently of R2 adreno-
ceptor blockage. These studies were extended to find additional compounds in these series
with improved properties. In such a way, substitution of both piperazine N atoms was first
optimized by using various alkyl, branched or not, and benzyl groups. Second, some
modifications of the imidazoline ring and its replacement by isosteric heterocycles were carried
out, proceeding from PMS 812, to evaluate their influence on the antidiabetic activity. The
importance of the distance between the imidazoline ring and the piperazine skeleton was studied
third. Finally, the influence of the N-benzyl moiety was also analyzed compared to a direct
N-phenyl substitution. The pharmacological evaluation was performed in vivo using glucose
tolerance tests on a rat model of type II diabetes. The most active compounds were
1,4-diisopropyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine (41a), PMS 847 (S-22068), and 1,4-
diisobutyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine (41b), PMS 889 (S-22575), which
strongly improved glucose tolerance without any side event or hypoglycemic effect. More
particularly, PMS 847 proved to be as potent after po (100 ímol/kg) as after ip administration
and appears as a good candidate for clinical investigations.
Introduction
Non-insulin-dependent diabetes mellitus (NIDDM) is
one of the most common chronic and dangerous diseases
with a prevalence of 4% in the Western world’s popula-
tion. Despite large efforts to discover new antidiabetic
drugs, only two classes of oral hypoglycemic agents
(sulfonylureas and biguanides) are available for the
treatment of NIDDM, and for both of them, a residual
insulin secretion is necessary for activity. Sulfonylureas,
such as tolbutamide and gliclazide, are hypoglycemic
compounds which stimulate insulin secretion via a well-
known mechanism.1 But a major drawback of sulfony-
lurea-based therapies is the occurrence of severe hy-
poglycemia. Biguanides (particularly metformine) act
mainly by decreasing gluconeogenesis and increasing
peripheral utilization of glucose.2-5 Among the most
promising therapeutic approaches, imidazoline deriva-
tives such as midaglizole,6,7 deriglidole,8,10 and efar-
oxan11 were reported to be antihyperglycemic agents.
In the past few years evidence occurred that the
insulin-secreting potency of imidazoline derivatives was
not correlated with their R2 antagonistic properties,12,13
and it has been proposed that some of these compounds
could interact with imidazoline preferring binding sites
(I-PBS).14,15
In a previous paper,16 we described the syntheses and
pharmaceutical evaluation of new antihyperglycemic
1,4-disubstituted-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-
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piperazines having the following general formula:
These compounds proved to be potent antihyperglycemic
agents in glucose tolerance tests using a rat model of
type II diabetes obtained by iv single injection of a low
dose (35 mg/kg) of streptozotocin (STZ rats). The struc-
ture-activity relationships obtained within this first
series showed that good potency was reached when R
is a short linear or branched alkyl chain and the phenyl
ring is substituted with halogens (more particularly
chlorine atoms). One of the most active compounds was
1-(2′,4′-dichlorobenzyl)-4-methyl-2-(4′,5′-dihydro-1′H-
imidazol-2′-yl)piperazine, PMS 812 (S-21663). Diabetic
rats treated with such compounds, especially PMS 812,
exhibited similar glycemia as nondiabetic control rats.16,17
None of the compounds of this series presented a potent
affinity for adrenoreceptors and I-PBS.16 Moreover PMS
812 was considered as a very efficient glucose-indepen-
dent insulin secretagogue acting through a novel imi-
dazoline site, linked to K+ channels, and distinct from
I1- and I2-PBS.18
In the continuation of this previous work,16 we report
here the synthesis and the biological evaluation of 1,4-
dialkyl-, 1,4-dibenzyl-, and 1-alkyl-4-benzyl(or phenyl)-
2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine deriva-
tives. Pharmacomodulation was also performed on the
imidazoline moiety itself which was substituted by a
methyl or replaced by isosteric groups such as oxazoline,
tetrahydropyrimidine, or amidine. All these compounds
were evaluated in vivo for their antidiabetic activity
using glucose tolerance tests. In vitro binding experi-
ments were performed on selected compounds and
showed the same negative results as observed in the
previous study.16
Chemistry
The 2-(4′,5′-dihydro-1′H-imidazol-2′-yl)- (41a-q, 42,
and 60-63), 2-(4′,5′-dihydro-1′,3′-oxaxazol-2′-yl)- (50),
and 2-(4′,5′-dihydro-1′H-imidazol-2′-yl)- (59) piperazines
were prepared from the corresponding esters synthe-
sized according to pathways described in Schemes 1-4.
Scheme 1 describes the synthesis of the major part
of the 1,4-alkylated and 1,4-benzylated ester derivatives.
Alkylation of ethyl piperazine-2-carboxylate (1)16 with
2 equiv of alkyl or allyl halides in refluxing acetone or
acetonitrile afforded the disubstituted compounds 2a-
g. In the case of chloro or bromo derivatives, the yields
of 2 were improved by addition of catalytic amounts of
KI.19 Selective alkylation in position 1 needed the use
of a protective group in position 4, i.e., triphenylmethyl
which was introduced by treating 1 at -10 °C with 1
equiv of trityl chloride. Ethyl 4-tritylpiperazine-2-car-
boxylate (3)16 was then alkylated into 5 and the trityl
group removed under acidic conditions leading to 6.
Reductive alkylation20 of 6 afforded the ethyl 1-alkyl-
4-methylpiperazine-2-carboxylate (7). Monosubstitution
of 1 in position 4 was performed in conditions depending
on the halide derivative. Ethyl 4-alkylpiperazine-2-
carboxylates 4 were achieved in refluxing acetone with
alkyl halides and at room temperature with allyl and
benzyl chlorides. In all cases a mixture of 4-monosub-
stituted and 1,4-disubstituted piperazine derivatives
was obtained, but the components were easily separated
by column chromatography on silica gel. No 1-N-
monosubstituted compound was detected, and this can
be explained by the steric hindrance due to the sub-
stituent in position 2. This effect disappears probably
by change of piperazine conformation after 4-N-alkyla-
tion.
When R is a phenyl or a dicyclopropylmethyl group
and R′ a methyl or a dicyclopropylmethyl moiety, the
corresponding N,N′-disubstituted ethylenediamine was
prepared before cyclization into the piperazine ring as
seen in Schemes 2 and 3. In Scheme 2, reductive
alkylation of commercial N-benzylaminoethanol af-
forded 9 which was converted to chloride 10 by treat-
ment with thionyl chloride. The amine 11, easily
purified by distillation, was then obtained in good yield
using an excess of ammonia (30 times more). Prolonged
heating (14 days) at 80 °C of 11 or ethylenediamine with
dicyclopropyl ketone was required to produce the imine
13 or diimine 14. After sodium borohydride reduction
(and catalytic debenzylation of compound 15), the
resulting amines 16 and 17 reacted with ethyl 2,3-
dibromopropionate to give 1-dicyclopropylmethyl-4-
methyl (18) and 1,4-bis(dicyclopropylmethyl) (19) ester
intermediates. Two isomers could be expected from the
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condensation of amine 17. Only the isomer 18 was
isolated. The reaction is a type II NS. The first attack
comes from the nonbulky nitrogen on C3 bromide of
ethyl 2,3-dibromopropionate. If the methyl group is
replaced by a more bulky substituent such as an
isopropyl group, the cyclization provided two regioiso-
mers,21 suggesting that steric control plays a major role
in determining the high selectivity.
N-Phenyl-substituted esters 24, 29, and 35 were
prepared using the corresponding 1-phenyl-4-alkyleth-
ylenediamines 23, 28, and 34. These diamines were
synthesized by three different pathways described in
Scheme 3. In method A, reaction of aniline with 0.5
equiv of benzoyl chloride followed by alkylation of the
resulting amide 20 with 2-chloro-1-N-methyl-N-benzyl-
aminoethane gave compound 21. Both protecting groups
were successively removed (i) by heating in acidic
medium to give 22 and (ii) then by catalytic hydro-
genolysis at room temperature leading to 23. If the
mixture was warmed at 50 °C or treated under pressure
(40 psi), the phenyl group was cleaved too. The diamine
28 could not be prepared by this method, because of the
cleavage of the N-isopropyl bond in strong acidic condi-
tions, but according to method B. The N-protection of
N-phenylethanolamine was selectively performed in
good yield using 0.5 equiv of benzyl chloride to afford
25. This alcohol was converted into the corresponding
tosylate 26 which reacted with isopropylamine to pro-
vide compound 27. Benzyl protecting group was then
removed by catalytic hydrogenolysis at room tempera-
ture affording 28. Because of the sensibility to hydro-
genolysis of the chloro substituent (Scheme 3, methods
A and B, step d), another protocol was used (method C)
for preparing diamine 34. 2-Chloroaniline was acylated
by benzoyl chloride and the resulting amide 30 alkylated
with chloroacetonitrile to give 31. Catalytic hydrogena-
tion of the nitrile in the presence of Raney nickel in
acetic anhydride afforded the diamide 32 which was
alkylated. Acidic hydrolysis of compound 33 provided
the diamine 34. Cyclization of the diamines 23, 28, and
34 with ethyl 2,3-dibromopropionate was difficult be-
cause of the low nucleophilicity of the nitrogen substi-
tuted with the aromatic ring. Anyway, the two possible
regioisomers were obtained. The ratio of the esters, 24a:
Scheme 1. Synthesis of Alkyl and Benzyl Ester
Intermediates 2a-g, 7a-d, and 8a-ca
a (a) MeCN or Me2CO, K2CO3, KI; (b) Ph3C-Cl, NEt3, CH2Cl2,
-10 °C; (c) HCl, Me2CO then Na2CO3; (d) HCO2H, HCHO, MeOH.
Scheme 2. Synthesis of Dicyclopropylmethyl Ester
Intermediates 18 and 19a
a (a) HCO2H, HCHO, MeOH then Na2CO3; (b) SOCl2; (c) NH3,
H2O; (d) C6H6; (e) NaBH4, MeOH; (f) H2, Pd/C, EtOH; (g) C6H6,
NEt3, 80 °C.
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24b (4:1), 29a:29b (7:3), and 35a:35b (1:9), depended
on the structure of the starting diamine. Only com-
pounds 24a, 29a, 29b, and 35b were isolated pure, the
percentage of minor isomer being determined by 1H
NMR.
The preparation of ethyl piperazin-2-ylacetate (40) is
described in Scheme 4. Ethyl 1,4-dibenzylpiperazine-2-
carboxylate16 was first reduced by AlLiH4 to afford the
intermediate 36. This alcohol was treated with thionyl
chloride to give chloride 37 which was then substituted
by CN-. Hydrolysis of the nitrile function of 38 by H2-
SO4 in EtOH afforded the corresponding ethyl 1,4-
dibenzylpiperazin-2-ylacetate (39). Its debenzylation led
to the key intermediate 40 which could be treated as
described in Scheme 1 to provide compounds 40a-c.
Imidazoline analogues were prepared according to
Neef general procedure22 with a minor modification16
(Scheme 5). Reaction of esters with ethylenediamine in
the presence of an excess of Al(CH3)3 provided the
imidazoline ring (41a-q, 60-63). N-Methylethylene-
diamine afforded the corresponding derivative 42. The
tetrahydropyrimidine 43 was prepared from 1,3-diami-
nopropane.
Both enantiomers of imidazoline derivative 41a were
tentatively prepared from (2R)- and (2S)-(1′R, 2′S, 5′R-
menthoxycarbonyl)piperazines obtained according to
Aebischer et al.23 These diastereoisomers were alkylated
with isopropyl iodide and the resulting esters converted
into the optically active imidazolines as described in
Scheme 5. Unfortunately these enantiomers were slowly
racemized in solution.21 For this reason, no further
investigation was performed on separation of enanti-
omers in these series (see Conclusion).
The synthetic strategy for preparing the oxazoline 50
is illustrated in Scheme 6. Compound 46 was prepared
first by N-benzylation of ethanolamine, then protection
Scheme 3. Synthesis of 1-Aryl-4-alkyl Ester Intermediates 24a,b, 29a,b, and 35a,ba
a (a) 0.5 equiv of Ph-COCl, CH2Cl2; (b) (1) NaH, DMF, 60 °C, (2) Bzl-N(Me)CH2-CH2-Cl; (c) 6 N HCl, EtOH/H2O; (d) H2, Pd/C, EtOH;
(e) Br-CH2CHBr-CO2-Et; (f) 0.5 equiv of Bzl-Cl, rt, C6H6; (g) Ts-Cl, NEt3, CHCl3, 0 °C; (h) Me2CHNH2, CH2Cl2; (i) (1) NaH, DMF, rt, (2)
Cl-CH2-CN; (j) Raney Ni, (MeCO)2O, H2 40 psi; (k) (1) NaH, DMF, rt, (2) MeI. *Isolated and purified for further syntheses.
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of the alcohol 44 using dihydropyran, and finally
removal of both benzyl protecting groups of the substi-
tuted ethanolamine 45. Condensation of the amine 46
with ester 7c in the presence of Al(CH3)3 afforded the
amide 47. After removal of the THP protecting group,
the resulting alcohol 48 was converted into the corre-
sponding chloride 49. Its cyclization in the presence of
NaOH gave the oxazoline analogue 50.
The synthesis of the amidines 52a, 52b, and 56
(Scheme 7) started from the cyanopiperazines 51 or 55
prepared by cyclization of N,N′-disubstituted ethylene-
diamine and 2,3-dibromopropionitrile in refluxing ben-
zene. According to Garigipati’s method,24 the amidines
52a, 52b and 56 were obtained from nitriles by addition
of methylchloroaluminum amides25 generated from tri-
methylaluminum and ammonium chloride or methy-
lamine hydrochloride.
The first step of the imidazole analogue 59 synthesis
(Scheme 8) was the reduction of ethyl 1-(2′,4′-dichlo-
robenzyl)-4-methylpiperazine-2-carboxylate into the al-
cohol 57.16 Subsequent oxidation into aldehyde 58 under
Swern’s conditions26 and then reaction with ammonia
and glyoxal27 gave the final product.
Scheme 4. Synthesis of Key Ester Intermediates 39
and 40a-ca
a (a) AlLiH4, THF; (b) SOCl2, CHCl3; (c) KCN, EtOH, H2O; (d)
H2SO4, EtOH, H2O; (e) H2, Pd/C, EtOH, HCl; (f) 40a-c were
prepared as for 2a, 7b, and 7d, respectively (Scheme 1).
Scheme 5. Syntheses of Final Imidazolines 41a-q, 42,
and 60-63 and Tetrahydropyrimidine 43
Scheme 6. Synthesis of Oxazoline Analogue 50a
a (a) (1) 2 equiv of C6H5CH2Cl, NEt3, (2) HCl; (b) DHP, CH2Cl2
then Na2CO3; (c) H2, Pd/C, EtOH; (d) 7c, AlMe3, toluene; (e) HCl,
MeOH then Na2CO3; (f) SOCl2, CHCl3 then Na2CO3; (g) NaOH.
Scheme 7. Syntheses of Amidine 52a and
Methylamidines 52b and 56a
a (a) Me2CH-I, K2CO3, KI; (b) H2, Pd/C, EtOH; (c) Br-CH2CH(Br)-
CN, C6H6, NEt3; (d) AlMe3, NH4Cl, C6H5Me; (e) AlMe3, CH3-NH2,
HCl, toluene.
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Significance and Validity of Pharmacological
Parameters. As previously described,16 antidiabetic
properties of all the synthesized compounds were evalu-
ated in vivo by their ability to improve the glucose
tolerance during intravenous glucose tests (IVGTT)
performed on a rat model of mild diabetes.28 This model
presents moderate basal hyperglycemia, glucose intoler-
ance, and impairment of the glucose-induced insulin
secretion which are the main features in patients with
NIDDM. IVGTT were carried out after a single ip
administration of 100 ímol/kg of each synthesized
molecule, and glucose tolerance was evaluated according
to three parameters: (i) G30, which is the glycemic value
at 30 min after glucose administration, (ii) ¢G, which
represents the increase of glycemia over the baseline
integrated over a period of 30 min following the glucose
load, and (iii) K, which is the rate of glucose disappear-
ance between 5 and 30 min after glucose administration.
To correct for the slight variations that appeared
when glucose tolerance tests were performed with
different control diabetic rats, we expressed the results
as a percentage (¢G*) of variation of ¢G between
treated and untreated diabetic rats:
In the same way, we defined G30* and K*. To be
considered as effective antidiabetics, compounds must
induce high percentages of variation for ¢G*, K*, and
G30*. Results around 100% or more indicate that the
parameters for the treated diabetic animals are close
to those obtained with nondiabetic control animals.
Among these three parameters, G30 which is obtained
via a direct measurement, is considered as the most
relevant when the compounds are tested po.
Results and Discussion
Within this new series, the first synthesized and
evaluated compounds were symmetrically substituted
on both piperazine nitrogen atoms by branched alkyl
or cycloalkyl chains.
The compounds 41a, 41b, and 41f, respectively sub-
stituted by two isopropyl, isobutyl, or 2-methylbutyl
groups, show potent effects on glycemia with values
similar to those of nondiabetic control rats. As in our
first paper,16 this correlates very well with their effects
on ¢G* and G30* with values around 100% (Table 1).
Their effect on the K parameter is also very significant
but less potent, since K* values remain between 47%
for compound 41a and 82% for compound 41f. The
derivatives 41c and 41g, substituted by two cyclopentyl
and neopentyl groups, are clearly less active on ¢G (¢G
* ) 58% and 54%, respectively) than their isobutyl
(compound 41b, ¢G * ) 141%) and 2-methylbutyl
(compound 41f, ¢G* ) 104%) analogues, probably due
to problems of steric hindrance. Concerning the com-
pound 41c, there is a slight discrepancy between the
effects on ¢G and K which is rather moderate and the
effect on G30 which is very high (G30* ) 103%). Com-
pound 41h, substituted by two dicyclopropylmethyl
groups, was slightly less active on ¢G (¢G* ) 24%). This
is not surprising if cyclopropyl molecular orbitals are
considered to have a partial ð character so that com-
pound 41h is comparable in some respects with the
dibenzyl-substituted imidazolinylpiperazines which were
found inactive in our first paper.16 Replacement of the
two isobutyl moieties (compound 41b) by two 2-methyl-
2-propenyl substituents (compound 41e) has no delete-
rious effect on the three parameters which are all
around 100%. This is not the case for the diallyl-
substituted compound 41d which is almost inactive
(¢G* ) 19%, G30* ) 30%, K* ) 35%).
Unsymmetrically substituted compounds (Table 1)
were then prepared and evaluated. The compounds 41l
and 41m, 4-methyl and respectively 1-isobutyl and
1-dicyclopropylmethyl substituted, are equipotent with
values around 100% for ¢G* and around 50% for G30*
and K*. It is noteworthy that compound 41m is much
more potent than its inactive symmetrically substituted
analogue 41h, while compound 41l is only slightly less
active than its analogue 41b but much more potent than
compound 41k (¢G* ) 40%, G30* ) 21%, K* ) 42%),
for which the methyl and isobutyl substituents have
been inverted. Surprisingly, while compound 41i, 1-isobu-
tyl, 4-allyl remains very potent (¢G* ) 115%), its
4-propenyl analogue 41j is clearly less active (¢G* )
53%). When compared to symmetrically substituted
compounds 41d and 41e, the results are inverted.
Compounds bearing a phenyl or a 2-chlorophenyl group
were finally synthesized and evaluated (compounds 41n,
41o, 41p, 41q). All of them proved to be inactive on ¢G
so that a phenyl substitution seems to be unfavorable.
An expected pKa variation cannot be taken into account.
In our first paper,16 we clearly demonstrated that the
protonation center at physiological pH in such series
was the imidazoline ring (pKa  9.5) and not the
piperazine one (pKa  5.5). Consequently this negative
effect should be due to a decrease of flexibility of these
molecules. Moreover, concerning compound 41o, sig-
nificant unexplainable discrepancies can be noticed
concerning the effects on ¢G and those on K and G30. It
is noteworthy that the 2-chlorobenzyl analogue of
compound 41p, PMS 774, is very potent (¢G* ) 81%,
K* ) 98%, G30* ) 103%).16
In a second step, chemical modulations on the imi-
dazoline pharmacophore itself were performed (Table
2). Insertion of a methylene spacer between the pipera-
zine and imidazoline rings results in a very clear
Scheme 8. Preparation of Imidazole Analogue 59a
a (a) LiAlH4, THF; (b) trifluoroacetic anhydride, DMSO, Et3N,
CH2Cl2, N2 atm; (c) glyoxal, NH3, MeOH.
¢G* ) j¢Gtreated STZ rats - ¢Guntreated STZ rats¢Guntreated STZ rats - ¢Gcontrol rats j  100
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decrease of hypoglycemic properties for three of the four
synthesized derivatives (60, 62, and 63). Concerning the
fourth compound, the dibenzyl derivative 61, a moderate
but clear effect on ¢G* is observed, while its analogue
without the methylene spacer was totally inactive.16 It
can be postulated that introduction of a spacer gives
more flexibility to this bulky molecule and consequently
allows a better access to a hypothetic imidazoline
binding site. Substitution of the imidazoline ring by a
methyl in position 1 (compound 42) leads to a poorly
active compound (¢G* ) 24%) as compared to its very
potent nonmethylated analogue PMS 812 (S-21663)
(¢G*) 105%). Replacement of the imidazoline by an
imidazole (compound 59) or an oxazoline (compound 50)
induces a total loss of activity. However only a partial
decrease in activity is observed for the tetrahydropyri-
midine analogue 43 (¢G* ) 47%) as compared to PMS
812 (¢G* ) 105%). The results obtained with amidine
and N-methylamidine are more contrasted. The N-
methylamidino diisopropyl compound 56 is clearly less
potent (¢G* ) 43%) than its imidazoline counterpart
41a (¢G* ) 138%), and the amidino 52a (¢G* ) 55%)
and N-methylamidino 52b (¢G* ) 50%) dibenzyl de-
rivatives are moderately active, while their imidazoline
analogue is totally inactive.16
Table 1. Variation of the Glycemia Parameters after ip
Administration of 100 ímol/kg of 1,4-Disubstituted-2-
(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines to STZ Ratsa
a Three-month-old male Wistar rats (250 g) treated with 35 mg/
kg iv of streptozotocin. b ¢G, incremental glycemia values over
baseline integrated over 30 min after glucose (0.5 g/kg iv)
administration. c G30, glycemia value 30 min after glucose admin-
istration. d K, rate of glucose disappearance between 5 and 30 min
after glucose administration.All results (asterisk) are expressed
as the percent of variation of the parameters between treated rats
(with an ip administration of 100 ímol/kg of the tested compound)
and untreated rats. Number of treated rats for each compound
included between 4 and 8 ((SEM).
Table 2. Variation of the Glycemia Parameters after ip
Administration of 100 ímol/kg of Substituted Imidazolines,
Tetrahydropyrimidine, Oxazoline, Amidines, Imidazole, and
2-Methylimidazoline to STZ Ratsa
a See footnotes of Table 1. b See formula in Introduction, PMS
812 or S-21663.
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Due to their good activity via ip administration,
compounds 41a, 41b, 41e, 41f, and 41i were selected
to be tested via po administration at 100 ímol/kg (Table
3). Among these five derivatives, only compounds 41a
and 41b proved to be active via po administration with
significant effects on G30* (respectively 73% and 66%).
This could be explained by the poor bioavailability of
the other compounds with (i) perhaps problems of
metabolism for the unsaturated compounds 41e and 41i,
despite their isolipophilicity (log P ) 1.45 and 1.30,
respectively) with the congener 41a, or (ii) a too high
hydrophobicity for compound 41f (log P ) 3.22) as
compared to 1.15 and 2.18 for compounds 41a and 41b,
respectively (cf. Table 3 and Experimental Section for
calculations). It seems that the range of lipophilicity
required for a good bioavailability of these compounds
is included between 2.2 and 1.1 units of log P ap-
proximately. Moreover, the log P value of PMS 812, a
very potent in vivo antihyperglycemic compound,16,17
was equal to 2.21.
Compound 41a was then selected for further phar-
macological studies and first evaluated for its capacity
to stimulate the secretion of insulin during IVGTT.
Surprisingly and unlike the substituted benzylpipera-
zine derivative PMS 812,16-18 compound 41a, PMS 847
(S-22068), has a poor stimulating effect on insulin
secretion.30
The in vitro binding experiments performed with
these compounds demonstrated that they were clearly
devoid of any affinity for the I1 and I2 binding sites as
well as for the R2 adrenoreceptor (KI g 10-5 M). This is
in agreement with an increasing number of studies
showing that R2 adrenergic antagonists are able to
stimulate insulin secretion independently of R2 and I1,
I2 blockage.16,17,28,29,31-38
Conclusion
In conclusion, 29 new imidazoline derivatives were
synthesized and evaluated (100 ímol/kg via ip admin-
istration) for their antidiabetic properties in glucose
tolerance tests. Seven of them (compounds 41a, 41b,
41e, 41f, 41i, 41l, and 41m) have a potent effect on the
glucose tolerance via ip administration, and 2 of them
(compounds 41a and 41b) were also found active after
po administration (100 ímol/kg). Surprisingly, com-
pound 41a (PMS 847, S-22068)30 has no effect on insulin
secretion and is devoid of any affinity either for the I1
and I2 imidazoline binding sites or for the R2 adreno-
receptors. This compound undergoes current comple-
mentary studies in order to investigate its possible
mechanism of action. Concurrently, the structure-
activity relationships that have been established with
this present work and the previous one16 show unam-
biguously that an unsubstituted imidazoline ring is a
required pharmacophore for potent antihyperglycemic
properties. All attempts to substitute it or to replace it
by imidazole, tetrahydropyrimidine, oxazoline, or ami-
dine result in a clear decrease or a total loss of activity.
This could be an argument for the involvement of
specific and still unknown imidazoline binding sites in
the regulation of glucose homeostasis.
Finally it is noteworthy that a spontaneous slow
racemization at the chiral carbon 2 is observed in such
molecules (cf. compound 41a, see Chemistry). This is a
consequence of a hydrogen transfer to the imidazoline
ring inducing an intermediate tautomeric form. It is
reasonable to suspect that such a phenomenon takes
place in vivo. If their exceptional conformational flex-
ibility is taken into account,16 such derivatives should
present great adaptability to special binding sites and
probably interact via dynamic processes.39
Experimental Section
Chemistry. General Methods. The purity of each com-
pound was checked by thin-layer chromatography on TLC
plastic sheets (silica gel 60F254, layer thickness 0.2 mm) from
Merck. Column chromatography purification was carried out
on silica gel 60 (particle size 0.063-0.200 mm) from Merck,
without any special treatment. All melting points were deter-
mined in a digital melting point apparatus (Electrothermal)
and are uncorrected. The structures of all compounds were
confirmed by IR and 1H NMR spectra. IR spectra were
obtained with an ATI Mattson Genesis Series FTIR infrared
spectrometer, and 1H NMR spectra were recorded in CDCl3
on a Brucker AC 200 spectrometer or a JEOL PMX60SI NMR
spectrometer using hexamethyldisiloxane (HMDS) as an in-
ternal standard. All elemental analyses were within (0.4%
of theoretical values.
Preparation of Alkyl and Benzyl Ester Intermediates
2a-g, 7a-d, and 8a-c (Scheme 1). Ethyl 1,4-Diisopro-
pylpiperazine-2-carboxylate Dihydrochloride (2a). A
suspension of 1â2HCl (23.1 g, 0.1 mol) and dry K2CO3 (40 g)
in 200 mL of acetonitrile was stirred for 1 h at room temper-
ature to regenerate the free amine; 51 g (0.3 mol) of isopropyl
iodide was added, and the mixture refluxed for 24 h. The
reaction mixture was cooled and filtered and the filtrate
diluted with ether. The organic layer was washed with water
and dried over MgSO4, and the solvents were removed in
vacuo. The crude product was dissolved in CH2Cl2, and after
the product was cooled in an ice bath, EtOH saturated with
HCl gas was added until acidic pH. The solvents were
evaporated and the dihydrochloride salt recrystallized from
CH2Cl2-acetone-ether to afford 22 g (72%) of 2aâ2HCl: mp
94-95 °C. Usual treatment of this salt gave free amine 2a as
a colorless oil: IR (film, cm-1) î 1755 (CdO); 1H NMR ä 4.16
Table 3. Variation of the Glycemia Parameters after po
Administration of 100 ímol/kg of 1,4-Disubstituted-2-
(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazines to STZ Rats and
Partition Coefficienta
a See footnotes of Table 1 and Experimental Section for calcula-
tion of log P.
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(2H, q, J ) 6.5 Hz, H2C-O), 3.40 (1H, dd, J ) 4.3 and 5.2 Hz,
HC-N), 2.95-2.38 (8H, ma, three H2C-N and two HC(CH3)2),
1.21 (3H, t, J ) 6.5 Hz, H3C-CH2O), 1.09, 0.96, 0.95, 0.90
(12H, 4d, J ) 6.5 Hz, two (H3C)2CH).
Compounds 2b-g (free amines as oils) were prepared by
the same procedure using acetone as solvent instead of
acetonitrile, catalytic amount of KI, and the corresponding
chloro or bromo derivative.
Ethyl 1,4-diisobutylpiperazine-2-carboxylate (2b): 1H
NMR ä 4.17-4.01 (2H, m, H2C-O), 3.16 (1H, dd, J ) 3.42
and 5.72 Hz, HC-N), 3.08-3.0, 2.73-2.64, 2.43-2.22 (7H, 3m,
three H2C-N and H-CH-N1), 2.12 (1H, dd, J ) 6.42 and 12.46
Hz, H-CH-N1), 1.97 (2H, d, J ) 7.66 Hz, H2C-N4), 1.73-1.56
(2H, m, two HC(CH3)2), 1.19 (3H, t, J ) 7.12 Hz, H3C-CH2O),
0.82 and 0.80 (12H, 2d in 1:3 ratio, two (H3C)2CH).
Ethyl 1,4-dicyclopentylpiperazine-2-carboxylate
(2c): 1H NMR ä 4.19-4.05 (2H, m, H2C-O), 3.42 (1H, dd, J
) 3.56 and 5.8 Hz, HC-N), 3.18-3.01, 2.81-2.73, 2.55-2.36,
1.78-1.27 (24H, 4m, in ratio 2:1:5:16, three H2C-N and H
cyclopentyl), 1.21 (3H, t, J ) 7.1 Hz, H3C-CH2O).
Ethyl 1,4-di(2′-propen-1′-yl)piperazine-2-carboxylate
(2d): 1H NMR ä 5.90-5.55 (2H, m, two HCd), 5.3-5.0 (4H,
m, H2Cd), 4.17 (2H, q, J ) 7.2 Hz, H2C-O), 3.62-2.0 (11H,
m, H piperazine and two H2C-CHd), 1.23 (3H, t, J ) 7.2 Hz,
H3C-CH2O).
Ethyl 1,4-di(2′-methyl-2′-propen-1′-yl)piperazine-2-car-
boxylate (2e): 1H NMR ä 4.85-4.46 (4H, m, two H2Cd), 4.15-
4.02 (2H, m, H2C-O), 3.22-2.22 (11H, m, H piperazine and
two H2C-CdC), 1.66 and 1.63 (6H, 2s, two H3C-C)), 1.20
(3H, t, J ) 7.1 Hz, H3C-CH2O).
Ethyl 1,4-di(2′-methylbutyl)piperazine-2-carboxylate
(2f): 1H NMR ä 4.15-4.02 (2H, m, H2C-O), 3.18-1.91 (9H,
m, H piperazine and two HC-N), 1.48-1.29 (4H, m, H2C-
CH3), 1.20 (3H, t, J ) 7.15 Hz, H3C-CH2O), 0.80 (6H, t, J )
6.87 Hz, two H3C-CH2), 0.81 and 0.79 (6H, 2d, J ) 6.87 Hz,
two H3C-CH).
Ethyl 1,4-dineopentylpiperazine-2-carboxylate (2g):
1H NMR ä 4.15-4.05 (2H, m, H2C-O), 3.22-2.5 (7H, m, H
piperazine), 1.9 (4H, s, two H2C-C(CH3)3), 1.2 (3H, t, J ) 7.17
Hz, H3C-CH2O), 0.75 (18H, s, (H3C)3-C).
Ethyl 4-(2′-Propen-1′-yl)piperazine-2-carboxylate (4a).
A suspension of 1 (23.1 g, 0.1 mol), dry K2CO3 (40 g), and KI
(4 g) in DMF (200 mL) was stirred vigorously and heated at
40 °C. After the mixture cooled, 1-bromo-2-propene (12.1 g,
0.1 mol) in DMF (80 mL) was added dropwise and the mixture
stirred at room temperature for 24 h. The solid material was
filtered and the filtrate diluted with ether and water. The
aqueous layer was extracted with ether. The organic layer was
dried over MgSO4 and concentrated. The crude product was
purified by column chromatography using petroleum ether/
ether (first 60:40 then 50:50, v/v) as eluent to give 6.1 g (31%)
of 4a as a yellow oil: IR (film, cm-1) î 3320 (N-H), 1740 (Cd
O); 1H NMR ä 5.85-5.68 (1H, m, HCd), 5.18-5.09 (2H, m,
H2Cd), 4.13 (2H, q, J ) 7.1 Hz, H2C-O), 3.66-2.10 (9H, m,
H piperazine and H2C-Cd), 1.97 (1H, s, D2O exchange, H-N),
1.20 (3H, t, J ) 7.1 Hz, H3C-CH2O).
Compounds 4b and 4c were prepared by the same procedure
using the corresponding bromo derivative.
Ethyl 1-Isobutyl-4-(triphenylmethyl)piperazine-2-car-
boxylate (5a). A mixture of 316 (40 g, 0.1 mol), dry K2CO3 (40
g), KI (4 g), and isobutyl bromide (16.4 g, 0.12 mol) in
acetonitrile (400 mL) was heated at 80 °C with stirring for 15
h. After filtration of solid material, the filtrate was diluted
with ether and washed with water. The aqueous layer was
extracted with ether, and the combined organic layers were
dried over MgSO4. Solvents were removed in vacuo, and this
crude 5a was used in the next step without purification.
Compounds 5b-d were prepared using the corresponding
chloro derivatives.
Ethyl 1-Isobutylpiperazine-2-carboxylate (6a). Crude
5a was dissolved in acetone (600 mL) containing 12 M HCl
(25 mL). After 3 h stirring at room temperature, the solvent
was removed in vacuo and the residue was partitioned between
ether and water. The aqueous layer was treated with a
saturated NaHCO3 solution until basic pH and extracted with
ether. The organic phase was dried over MgSO4 and the
solvent evaporated under vacuo. The crude product was
purified by column chromatography using first petroleum
ether/ether (30:70, v/v) and then ether to afford 17 g (80%) of
6a as a colorless oil: IR (film, cm-1) î 3340 (N-H), 1740 (Cd
O); 1H NMR ä 4.15 (2H, q, J ) 7.1 Hz, H2C-O), 3.19-1.99
(7H, m, H piperazine), 1.96 (2H, d, J ) 7.68 Hz, H2C-CH),
1.73-1.56 (1H, m, HC(CH3)2), 1.5 (1H, br s, D2O exchange,
H-N), 1.23 (3H, t, J ) 7.1 Hz, H3C-CH2O), 0.82 (6H, d, J )
6.4 Hz, (H3C)2CH).
Compounds 6b-d were prepared using the same procedure.
Ethyl 1-Isobutyl-4-methylpiperazine-2-carboxylate (7a).
A mixture of 6a (17 g, 0.08 mol), 37% formaldehyde (10 mL,
0.13 mol), and formic acid (10 mL, 0.25 mol) in MeOH (110
mL) was refluxed for 20 h. After evaporation of the solvent,
the residue was taken up in ether and washed with saturated
NaHCO3 solution until basic pH. The organic layer was
washed with water and dried over MgSO4, and the solvent was
removed in vacuo. The crude product was purified by crystal-
lization of the hydrochloride salt from ethanol-ether. Usual
treatment of this salt afforded 15.5 g (85%) of 7a as a colorless
oil: IR (film, cm-1) î 1745 (CdO); 1H NMR ä 4.15 (2H, q, J )
7.10 Hz, H2C-O), 3.07-2.20 (7H, m, H piperazine), 2.27 (3H,
s, H3C-N), 2.02 (2H, d, J ) 7.29 Hz, H2C-CH), 1.79-1.59
(1H, m, HC(CH3)2), 1.22 (3H, t, J ) 7.10 Hz, H3C-CH2O), 0.81
(6H, d, J ) 6.33 Hz, (H3C)2CH).
Compounds 7b-d were prepared using the same procedure.
Ethyl 1-(2′,4′-dichlorobenzyl)-4-methylpiperazine-2-
carboxylate (7b): 1H NMR ä 7.38-7.11 (3H, m, Ar-H), 4.06
(2H, q, J ) 7.09 Hz, H2C-O), 3.75 and 3.44 (2H, AB spectrum,
J ) 14.76 Hz, H2C-Ar), 3.6-2.24 (7H, m, H piperazine), 2.19
(3H, s, H3C-N), 1.16 (3H, t, J ) 7.09 Hz, H3C-CH2O).
Ethyl 1-(2′-chlorobenzyl)-4-methylpiperazine-2-car-
boxylate (7c) and ethyl 1-(2′-methoxybenzyl)-4-meth-
ylpiperazine-2-carboxylate (7d): 1H NMR spectra were the
same as for 7b; particular signal for 7d ä 6.69 (3H, s, H3C-
O).
Ethyl 1-Isobutyl-4-(2′-propen-1′-yl)piperazine-2-car-
boxylate (8a). This compound was prepared following the
procedure described for 5a, starting from 4a (19.8 g, 0.1 mol)
and isobutyl bromide (16.4 g, 0.12 mol). After treatment the
crude product was purified by column chromatography using
petroleum ether/ether (first 70:30 then 50:50, v/v) as eluent
to afford 18 g (71%) of 8a as a colorless oil: IR (film, cm-1) î
1745 (CdO); 1H NMR ä 5.79-5.75 (1H, m, HCd), 5.24-5.14
(2H, m, H2Cd), 4.12 (2H, q, J ) 7.2 Hz, H2C-O), 3.10-2.24
(11H, m, H piperazine, H2C-Cd and H2C-CH(CH3)2), 1.72-
1.62 (1H, m, H-C(CH3)2, 1.19 (3H, t, J ) 7.2 Hz, H3C-CH2O),
0.82 and 0.79 (6H, 2d, J ) 6.2 Hz, (H3C)2CH).
Ethyl 1-isobutyl-4-(2′-methyl-2′-propen-1′-yl)piperazine-
2-carboxylate (8b): prepared like compound 8a starting from
4b; 1H NMR ä 4.77 (2H, br s, H2Cd), 4.45-4.15 (2H, m, H2C-
O), 3.20-2.08 (11H, H piperazine, H2C-N1 and H2C-N4), 1.63
(3H, s, H3C-Cd), 1.20 (3H, t, J ) 7.13 Hz, H3C-CH2O), 0.82
and 0.79 (6H, 2d, J ) 6.35 Hz, (H3C)2CH).
Ethyl 1-methyl-4-isobutylpiperazine-2-carboxylate (8c):
obtained as described for 7a starting from 4c; 1H NMR ä 4.14
(2H, q, J ) 7.1 Hz, H2C-O), 3.71-2.12 (7H, m, H piperazine),
2.27 (3H, s, H3C-N), 2.02 (2H, d, J ) 7.37 Hz, H2C-N), 1.79-
1.59 (1H, m, HC(CH3)2), 1.22 (3H, t, J ) 7.10 Hz, H3C-CH2O),
0.81 (6H, d, J ) 7.37 Hz, (H3C)2CH).
Preparation of Dicyclopropylmethyl Ester Intermedi-
ates 18 and 19 (Scheme 2). N-Benzyl-N-methylethanol-
amine (9). This compound was prepared following the same
procedure as for 7a. The crude product was purified by
distillation (E15 ) 140-142 °C); 151 g (1 mol) of N-benzyl-
ethanolamine afforded 138 g (84%) of 9: IR (film, cm-1) î 3500
(OH), 1590 (CdC); 1H NMR ä 7.20 (5H, s, Ar-H), 3.80 (1H, br
s, D2O exchange, H-O), 3.54 (2H, t, J ) 5.6 Hz, H2C-O), 3.49
(2H, s, H2C-Ar), 2.47 (2H, t, J ) 5.6 Hz, H2C-N), 2.13 (3H,
s, J ) 7.2 Hz, H3C-N).
Imidazoline Derivatives Active on Glucose Homeostasis Journal of Medicinal Chemistry, 1999, Vol. 42, No. 9 1595
2-Chloro-N-benzyl-N-methylethylamine Hydrochlo-
ride (10). To 130 g (0.79 mole) of 9 in CHCl3 (400 mL) was
added dropwise 70 mL of SOCl2 in CHCl3 (70 mL). After 15 h
stirring at room temperature, the solvent was removed in
vacuo. The residue was crystallized from acetone/MeOH (80:
20, v/v) to give 146 g (84%) of 10 as a white powder: mp 140-
141 °C; IR (free base, film, cm-1) 1595 î (CdC); 1H NMR (free
base) ä 7.24 (5H, m, Ar-H), 3.54 (2H, s, H2C-Ar), 3.53 (2H, t,
J ) 6.8 Hz, H2C-Cl), 2.69 (2H, t, J ) 6.8 Hz, H2C-N), 2.21
(3H, s, H3C-N).
N-Benzyl-N-methylethylenediamine (11). 10 (110 g, 0.5
mol) was solubilized in a 28% aqueous ammonia solution (1
L) and stirred for 3 days at room temperature. The water was
partially removed in vacuo, and 28 g of KOH pellets was added.
The aqueous layer was extracted with CH2Cl2, and the organic
layer was dried over MgSO4 and concentrated. The crude
product was purified by distillation (E15 ) 152-154 °C) to give
49 g (60%) of 11: IR (film, cm-1) î 3410 and 3405 (NH2), 1590
(CdC); 1H NMR (60 MHz) ä 7.18 (5H, s, Ar-H), 3.41 (2H, s,
H2C-Ar), 2.80-2.20 (4H, m, two H2C-N), 2.10 (3H, s, H3C-
N), 1.12 (2H, br s, D2O exchange, H2N).
N-Benzyl-N-methyl-N′-(dicyclopropylmethyl)ethylene-
diamine (15). A mixture of 8.2 g (0.05 mol) of 11 and 5.5 g
(0.05 mol) of dicyclopropyl ketone in benzene (50 mL) was
refluxed for 15 days using a Dean-Stark apparatus. Advance-
ment of the reaction was followed by IR. The solvent was
evaporated, and the residue was diluted in dry and cold MeOH
(50 mL); then 1.9 g (0.05 mol) of NaBH4 was added portionwise.
After 15 h stirring at room temperature, the mixture was
poured into water containing 2 g of NaOH, saturated with
NaCl, and extracted with hexane. The organic layer was dried
over MgSO4 and concentrated. The crude product was purified
by column chromatography using CH2Cl2 and then CH2Cl2/
MeOH (97:3, v/v) as eluents to give 5.2 g (40%) of 15: IR (film,
cm-1) î 3380 (NH), 3100, 3080 (cyclopropyl), 1580 (CdC); 1H
NMR (60 MHz) ä 7.19 (5H, s, Ar-H), 3.45 (2H, s, H2C-Ar),
2.95-2.67 (4H, m, two H2C-N), 1.90 (1H, s, D2O exchange,
H-N), 1.35-0.48 (11H, m, HC-dicyclopropyl and H cyclopro-
pyl).
N-Methyl-N′-(dicyclopropylmethyl)ethylenediamine
(17). A shaken suspension of 15 (23 g, 0.09 mol) and 10% Pd/C
(300 mg) in anhydrous ethanol (120 mL) was heated at 40 °C
under H2 atmosphere for 3 h. The reaction mixture was filtered
through Celite and concentrated. The crude product was
purified by distillation (E0.05 ) 48-52 °C) to give 12.8 g (85%)
of 17 as a colorless oil: IR (film, cm-1) î 3400 (NH), 3100, 3080
(cyclopropyl); 1H NMR (60 MHz) ä 2.95-2.50 (4H, m, two
H2C-N), 1.75 (2H, s, D2O exchange, two H-N), 1.35-0.45
(11H, m, HC-dicyclopropyl and H cyclopropyl).
Ethyl 1-(Dicyclopropylmethyl)-4-methylpiperazine-2-
carboxylate (18). To a hot (80 °C) stirred solution of 17 (12
g, 0.07 mol) and triethylamine (24 mL, 0.17 mol) in toluene
(100 mL) was added dropwise, but rapidly, ethyl 2,3-dibro-
mopropionate (18.3 g, 0.071 mol) in toluene (100 mL). After
the addition, the reaction mixture was stirred at 80 °C for 3
h, then cooled, and filtered. The filtrate was washed with
saturated aqueous NaHCO3 (100 mL). The organic layer was
dried over MgSO4 and the solvent removed in vacuo. The crude
product was purified by column chromatography using petro-
leum ether/ether (80:20, v/v) as eluent to afford 9.5 g (54%) of
18 as a pale-yellow oil: IR (film, cm-1) î 3100, 3080 (cyclo-
propyl), 1745 (CdO); 1H NMR ä 4.08 (2H, q, J ) 7.2 Hz, H2C-
O), 4.03 (1H, t, J ) 6.3 Hz, HC-N), 3.23-3.04, 2.74-2.70,
2.60-2.38 (6H, 3m, three H2C-N), 2.25 (3H, s, J ) 7.2 Hz,
H3C-N), 1.49 (1H, t, J ) 9 Hz, HC-dicyclopropyl), 1.26 (3H, t,
J ) 7.2 Hz, H3C-CH2O), 0.9-0.76, 0.56-0.1 (10H, 2m, H
cyclopropyl).
Ethyl 1,4-Bis(dicyclopropylmethyl)piperazine-2-car-
boxylate (19). Compound 19 was obtained similarly, starting
with disubstituted ethylenediamine 16: 1H NMR ä 4.15-3.95
(3H, m, H2C-O and HC-N), 3.15-2.73 (6H, m, three H2C-
N), 1.45 (1H, t, J ) 9 Hz, HC-dicyclopropyl), 1.06 (1H, t, J )
8.5 Hz, HC-dicyclopropyl), 1.18 (3H, t, J ) 7.1 Hz, H3C-CH2O),
0.8-0.69, 0.47-0.08 (20H, 2m, H cyclopropyl).
Preparation of 1-Phenyl-4-alkyl Ester Intermediates
24a, 29a,b, and 35b (Scheme 3). N-Benzoylaniline (20).
To a cold solution of 150 mL (1.65 mol) of aniline in CH2Cl2
(400 mL) was added dropwise 90 mL (0.776 mol) of benzoyl
chloride in CH2Cl2 (200 mL). After 2 h stirring at room
temperature, water (300 mL) and concentrated HCl (20 mL
at 37%) were added. The mixture was filtered and the solid
product washed with water and then with acetone to afford
120 g of 20. The filtrate was concentrated to provide another
28 g of 20 (global yield 97%): mp 162-164 °C; IR (film, cm-1)
î 3399 (NH), 1642 (CdO); 1H NMR ä 7.82 (1H, br s, D2O
exchange, H-N), 7.80-7.04 (10H, m, Ar-H).
N-Benzoyl-N-phenyl-N′-benzyl-N′-methylethylenedi-
amine (21). To a stirred cold suspension of NaH (25 g, 0.625
mol) in DMF (100 mL) was added dropwise the amide 20 (118
g, 0.6 mol) in DMF (500 mL). The mixture was stirred for 1 h
at room temperature, and then 105 g (0.57 mol) of 2-chloro-
N-benzyl-N-methylethylamine dissolved in DMF (100 mL) was
added. The solution was stirred and heated for 3 h at 60 °C,
and after the solution had cooled in an ice bath, water (500
mL) was added. The aqueous layer was extracted several times
with ether and the etheral layer washed with aqueous HCl
until acidic pH. The aqueous layer was extracted with CH2-
Cl2 (the hydrochloride salt of compound 21 is very soluble in
CH2Cl2) and the organic layer washed with aqueous Na2CO3
until basic pH. The dichloromethane phase was dried over
MgSO4 and concentrated. The crude product was crystallized
from pentane/ether (90:10, v/v) to give 120 g (58%) of 21 as a
white powder: mp 52.5-53 °C; IR (KBr, cm-1) î 1634 (CdO),
1594 (CdC); 1H NMR ä 7.22-6.92 (15H, ma, Ar-H), 4.00 (2H,
t, J ) 6.8 Hz, H2C-N), 3.46 (2H, s, H2C-Ar), 2.62 (2H, t, J )
6.8 Hz, H2C-N′), 2.14 (3H, s, H3C-N′).
N-Phenyl-N′-benzyl-N′-methylethylenediamine (22).
21 (120 g, 0.35 mol) was solubilized in 1 L of HCl (6 M) and
refluxed for 24 h. After cooling in an ice bath and filtration of
benzoic acid, the water was partially evaporated. The aqueous
solution was extracted twice with CH2Cl2, treated with Na2-
CO3 until basic pH, and then re-extracted with CH2Cl2. The
organic layer was dried over MgSO4 and concentrated to afford
81 g (96%) of 22 as a colorless oil: IR (film, cm-1) î 3389 (NH),
1603 (CdC); 1H NMR ä 7.23-6.52 (10H, m, Ar-H), 4.18 (1H,
br s, D2O exchange, H-N), 3.45 (2H, s, H2C-Ar), 3.09 (2H, t,
J ) 5.6 Hz, H2C-N), 2.58 (2H, t, J ) 5.6 Hz, H2C-N′), 2.13
(3H, s, H3C-N′).
N-Phenyl-N′-methylethylenediamine Dihydrochloride
(23). A shaken suspension of 22 (80 g, 0.33 mol) and 10% Pd/C
(600 mg) in anhydrous ethanol (300 mL) was kept under an
H2 atmosphere for 24 h at room temperature. The solution was
filtered; the filtrate was diluted with EtOH/HCl and then
concentrated; 65.5 g (89%) of 23 was obtained as a white
powder: mp 153-168 °C dec; IR (free base, film, cm-1) î 3391
(NH), 1603 (CdC); 1H NMR (free base) ä 7.15-7.05, 6.65-
6.52 (5H, 2m, Ar-H), 4.16 (1H, br s, D2O exchange H-N), 3.11
(2H, t, J ) 6.1 Hz, H2C-N), 2.73 (2H, t, J ) 6.1 Hz, H2C-N′),
2.34 (3H, s, H3C-N′), 1.55 (1H, br s, D2O exchange, H-N′).
Ethyl 1-Phenyl-4-methylpiperazine-2-carboxylate (24a).
The title compound was prepared according to the procedure
used for 18, starting from 65 g (0.29 mol) of 23 dihydrochloride
salt (the free base was regenerated in situ). The crude product
was purified by column chromatography using petroleum
ether/ether (first 80:20 then 70:30, v/v) as eluent, to afford 27
g (39%) of the two isomers 24a and 24b. The pure isomer 24a
was obtained by crystallization of the dihydrochloride salt from
acetone-ether and then recrystallized from acetone/ethanol
(90:10, v/v): mp 159 °C. The mother liquor was concentrated,
and the residue, after alkalization, gave a pale-yellow oil,
mixture of the two isomers 24a and 24b in the ratio 1:1; IR
(free base, film, cm-1) of 24a: î 1743 (CdO), 1599 (CdC); 1H
NMR ä 7.18-7.10, 6.77-6.67 (5H, 2m, Ar-H), 4.36 (1H, t, J
) 3.3 Hz, H-N)*, 4.00 (2H, dq, J ) 6.5 and 1.8 Hz, H2C-O),
3.46-2.04 (6H, 3m, three H2C-N), 2.20 (3H, s, H3C-N), 1.05
(3H, t, J ) 6.5 Hz, H3C-CH2O). *This signal allowed to
determine the ratio of the isomers. It presents 0.5H in the
mixture obtained from the mother liquor.
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N-Benzyl-2-anilinoethanol (25). To 175.5 g (1.28 mol) of
2-anilinoethanol in benzene (200 mL) was added 79 g (0.625
mol) of benzyl chloride. The solution was stirred for 48 h at
room temperature, then water (200 mL) was added, and the
aqueous layer was extracted with ether. The organic phase
was dried over MgSO4 and concentrated. The residue was
taken up in aqueous HCl and extracted with CH2Cl2 (the
hydrochloride salt of 25 is very soluble in CH2Cl2). The organic
layer was neutralized and dried over MgSO4 and the solvent
evaporated. The crude product was purified by distillation
(E0.05 ) 145-147 °C) to give 80 g (56%) of 25: IR (KBr, cm-1)
î 3568-3531 (OH), 1598 (CdC); 1H NMR ä 7.20-7.05, 6.70-
6.60 (10H, 2m, Ar-H), 4.50 (2H, s, H2C-Ar), 3.68 (2H, dt, J
) 5.66 and 5.60 Hz, H2C-O), 3.49 (2H, t, J ) 5.66 Hz, H2C-
N), 1.83 (1H, t, J ) 5.60 Hz, D2O exchange, H-O).
N-Benzyl-N-phenyl-2-(p-tolylsulfonyloxy)ethylamine
(26). 25 (113.5 g, 0.5 mol) was dissolved in chloroform (500
mL) and cooled in a salted ice bath. Et3N (83 mL, 0.6 mol)
was then added, followed by the addition of 95.2 g (0.5 mol) of
p-toluenesulfonyl chloride in one portion with constant stirring.
The reaction was complete in 24 h at 0 °C. Ether (200 mL)
was added, and the precipitate of triethylamine hydrochloride
was filtered. The filtrate was concentrated in vacuo and the
residue dissolved in ether. The etheral phase was washed
successively with diluted HCl and water. The organic layer
was dried over MgSO4, and the solvent was removed under
reduced pressure. The crude tosylate was purified by crystal-
lization from hexane/CH2Cl2 to give 26 (127 g, 67%) as white
crystals: mp 82-84 °C; IR (KBr, cm-1) î 1598 (CdC); 1H NMR
ä 7.64 (2H, d, J ) 8.30 Hz, 2H in ortho of Ar-SO2), 7.25-6.52
(12H, m, Ar-H), 4.41 (2H, s, H2C-Ar), 4.11 (2H, t, J ) 6.40
Hz, H2C-O), 3.61 (2H, t, J ) 6.40 Hz, H2C-N), 2.34 (3H, s,
H3C-Ar).
N-Benzyl-N-phenyl-N′-isopropylethylenediamine (27).
An amount of 150 mL (1.74 mol) of isopropylamine was added
to 114 g (0.3 mol) of tosylate 26 in CH2Cl2 (200 mL). After 8
days stirring at room temperature, the solvent and excess of
isopropylamine were evaporated under reduced pressure. The
residue was treated with ether and 2 M NaOH until basic pH.
The aqueous layer was extracted with ether, the extracts were
dried over MgSO4, and the solvent was removed in vacuo. The
diamine 27 was purified by crystallization of its hydrochloride
salt from ether/ethanol. After alkylization, 57 g (71%) of 27
was obtained as a pale-yellow oil: IR (KBr, cm-1) î 3316 (NH),
1598 (CdC); 1H NMR ä 7.25-7.07, 6.70-6.57 (10H, 2m, Ar-
H), 4.50 (2H, s, H2C-Ar), 3.48 (2H, t, J ) 6.80 Hz, H2C-N),
2.82 (2H, t, J ) 6.80 Hz, H2C-N′), 2.67 (1H, hp, J ) 6.20 Hz,
HC(CH3)2), 1.31 (1H, br s, D2O exchange, H-N), 0.94 (6H, d,
J ) 6.20 Hz, (H3C)2CH).
N-Phenyl-N′-isopropylethylenediamine Dihydrochlo-
ride (28). This compound was prepared in a similar way as
17, starting from 27 (53 g, 0.20 mol). The crude product was
dissolved in CH2Cl2, and after it had cooled in an ice bath,
C2H5OH saturated with HCl gas was added until acidic pH.
The solvent was evaporated and the dihydrochloride salt
recrystallized from acetone/ethanol (90:10, v/v) to afford 35 g
(70%) of 28 as a white powder: mp 154 °C; IR (KBr, cm-1) î
3371 (NH), 1599 (CdC); 1H NMR (free base)ä 7.19-7.05, 6.67-
6.55 (4H, 2m, Ar-H), 4.19 (1H, t, D2O exchange, H-N-Ar),
3.19 (2H, t, J ) 5.50 Hz, H2C-N), 2.84-2.69 (3H, m, H2C-N′
and HC(CH3)2), 2.09 (1H, br s, D2O exchange, H-N′), 1.03 (6H,
d, J ) 6.30 Hz, (H3C)2CH).
Ethyl 1-Phenyl-4-isopropylpiperazine-2-carboxylate
(29a) and Ethyl 1-Isopropyl-4-phenylpiperazine-2-car-
boxylate (29b). The title compounds were prepared according
to the procedure used to dispose 18, starting from 32 g (0.127
mol) of 28 dihydrochloride salt (the free base was regenerated
in situ). Compounds 29a and 29b were separated by column
chromatography using petroleum ether/ether (90:10, 85:15, 80:
20, v/v) as eluent. 29a: 15 g (43%); mp 70-72 °C (hexane); 1H
NMR spectrum of this ester was similar to that of 24a;
particular signal ä 0.97 and 0.93 (6H, 2d, J ) 6.6 Hz, (H3C)2-
CH). 29b: 6 g (17%), pale-yellow oil (after crystallization of
the dihydrochloride salt from acetone/hexane/CH2Cl2 and
regeneration of the free base); 1H NMR ä 7.23-7.14, 6.86-
6.75 (5H, 2m, Ar-H), 4.15 (2H, q, J ) 7.1 Hz, H2C-O), 3.58
(1H, t, J ) 5.9 Hz, HC-N), 3.35-2.94 (6H, m, three H2C-N),
2.68-2.57 (1H, m, HC(CH3)2), 1.22 (3H, t, J ) 1 Hz, H3C-
CH2O), 1.10 and 0.94 (6H, 2d, J ) 6.5 Hz, (H3C)2CH).
N-Benzoyl-o-chloroaniline (30). To a cold solution of 132
g (1.035 mol) of o-chloroaniline in CH2Cl2 (300 mL) was added
dropwise 60 mL (0.517 mol) of benzoyl chloride in CH2Cl2 (200
mL). After 2 h stirring at room temperature, the hydrochloride
salt of o-chloroaniline was filtered and the filtrate washed first
with diluted HCl and then with water. The organic layer was
dried over MgSO4 and concentrated in vacuo. The product
crystallized from hexane to afford 108 g (90%) of 30 as a white
powder: mp 163 °C; IR (KBr, cm-1) î 1642 (CdO), 1596 (Cd
C); 1H NMR ä 8.50 (1H, d, J ) 7.96 Hz, Ar-H), 8.39 (1H, s,
D2O very slow exchange, H-N), 7.88-6.98 (8H, m, Ar-H).
N-Benzoyl-N-(o-chlorophenylamino)acetonitrile (31).
To a cold suspension of NaH (14 g, 0.35 mol) in DMF (100
mL) was added dropwise the amide 30 (75 g, 0.324 mol) in
DMF (300 mL). The mixture was stirred for 2 h at room
temperature; then 25 g (0.33 mol) of 2-chloroacetonitrile
dissolved in DMF (100 mL) was added dropwise. The solution
was stirred for 15 h and then poured into iced water (500 mL).
The aqueous layer was extracted several times with ether and
the extract dried over MgSO4 and concentrated. The crude
product crystallized from hexane/CH2Cl2 to give 46 g of 31 as
a white powder: mp 93 °C. The mother liquor was concen-
trated and purified by column chromatography using petro-
leum ether/ether/CH2Cl2 (70:20:10, v/v/v) as eluent, to give 17
g of 31 (total yield 72%): IR (KBr, cm-1) î 2242 (CN), 1642
(CdO), 1596 (CdC); 1H NMR ä 7.38-7.08 (9H, m, Ar-H), 5.05
and 4.21 (2H, 2d, J ) 17.1 Hz, H2C-CN).
N-Benzoyl-N-(o-chlorophenyl)-N′-acetylethylenedi-
amine (32). A mixture of 31 (27 g, 0.1 mol), dry CH3CO2Na
(12 g), and Raney nickel in 200 mL of acetic anhydride was
heated at 50 °C and hydrogenated on a Parr hydrogenator
apparatus under a 40-50 psi pressure for 18 h. The catalyst
was separated by decantation and the solvent removed under
vacuo. The crude product was dissolved in CH2Cl2, the solution
washed with water and then dried over MgSO4, and the
solvent removed. Addition of ether to the residue gave 22 g of
32. The mother liquor was concentrated and then chromato-
graphed using CH2Cl2/MeOH (99:1, v/v) as eluent to afford 5
g of 32 (total yield 27 g, 85%): mp 138.5-139 °C; IR (KBr,
cm-1) î 3257 (NH), 1650 (CdO), 1595 (CdC); 1H NMR ä 7.27-
7.03 (9H, m, Ar-H), 6.86 (1H, br s, D2O exchange, H-N), 4.29,
3.56 and 3.30 (4H, 3m in 1:2:1 ratio, H2C-N and H2C-N′),
1.89 (3H, s, H3C-CdO).
N-(o-Chlorophenyl)-N-benzoyl-N′-acetyl-N′-methyleth-
ylenediamine (33). To a cooled (0 °C) suspension of NaH (3.6
g, 0.09 mol) in DMF (50 mL) was added dropwise the diamide
32 (25.9 g, 0.082 mol) in DMF (100 mL). The mixture was then
stirred for 3 h at room temperature, and 13 g (0.09 mole) of
methyl iodide dissolved in DMF (30 mL) was added dropwise.
The solution was stirred overnight, then poured into cold water
(500 mL), and extracted with CH2Cl2. The organic layer was
dried over MgSO4, and the solvents were evaporated in vacuo
to dryness. The crude product 33 was used in the next step
without purification.
N-(o-Chlorophenyl)-N′-methylethylenediamine Dihy-
drochloride (34). This compound was prepared using the
procedure described to prepare compound 22 except the time
of the reaction (48 h). The hydrochloride salt was crystallized
from acetone/ethanol (90:10, v/v) to afford 10 g (47% for the
two steps) of 34: mp 116 °C; IR (KBr, cm-1) î 3337 (NH), 1599
(CdC); 1H NMR ä 7.20-7.02, 6.63-6.51 (4H, 2m, Ar-H), 4.62
(1H, br s, D2O exchange, H-N), 3.21 (2H, t, J ) 6.1 Hz, H2C-
N), 2.82 (2H, t, J ) 6.1 Hz, H2C-N′), 2.41 (3H, s, H3C-N′),
2.35 (1H, s, D2O exchange, H-N′).
Ethyl 1-Methyl-4-(2′-chlorophenyl)piperazine-2-car-
boxylate (35b). The title compound was prepared according
to the procedure used to prepare 18 starting from 16 g (0.062
mol) of 34 dihydrochloride salt (the free base was regenerated
in situ). Two successive purifications by column chromatog-
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raphy using petroleum ether/ether (85:15, v/v) as eluent
afforded 3.8 g (22%) of pure 35b as a pale-yellow oil and 0.8 g
of a mixture of the two isomers 35a and 35b in a 1:1 ratio.
The 1H NMR spectrum of 35b was similar to that of 29b,
particular signal ä 2.35 (3H, s, H3C-N).
Preparation of the Ester Intermediates 39 and 40a-c
(Scheme 4). 1,4-Dibenzyl-2-(hydroxymethyl)piperazine
(36). A stirred suspension of LiAlH4 (5 g, 0.13 mol) in dry
tetrahydrofuran (200 mL) was cooled at 0 °C, and 57 g (0.17
mol) of ethyl 1,4-dibenzylpiperazine-2-carboxylate in tetrahy-
drofuran (200 mL) was added. The mixture was stirred for 20
h at room temperature, then cooled, and treated carefully with
aqueous NaOH (20%). The aqueous layer was extracted with
CH2Cl2, and the extracts were dried over MgSO4. After the
solvents were removed, crystallization of the crude product
afforded 47 g (93%) of 36 as a white powder: mp 70-72 °C;
IR (KBr, cm-1) î 3400 (OH), 1600 (CdC); 1H NMR (500 MHz)
ä 7.22 (10H, m, Ar-H), 4.05 and 3.58 (2H, two dd, J ) 11.14
and 2.86 Hz, H2C-O), 3.98 and 3.47 (2H, 2d, J ) 13.2 Hz,
H2C-Ar), 3.49 (2H, s, H2C-Ar), 2.56 (1H, s, D2O exchange,
H-O), 2.98-2.94 (1H, m, HC-N), 2.69-2.60, 2.52-2.44 and
2.40-2.37 (6H, 3m, H2C-N).
1,4-Dibenzyl-2-(chloromethyl)piperazine (37). Com-
pound 37 was prepared according to the procedure used to
dispose 10. The crude product obtained from 20 g (0.068 mol)
of 36 was partitioned between ether and water. The aqueous
layer was treated with Na2CO3 and extracted with CHCl3. The
organic layer was dried over MgSO4 and the solvent removed
in vacuo. The residue was purified by column chromatography
using petroleum ether/ether (90:10, v/v) as eluent, to afford
17 g (79%) of 37 as a yellow oil: IR (film, cm-1) î 1600 (CdC);
1H NMR ä 7.23 (10H, br s, Ar-H), 3.97 and 3.54 (2H, AB
spectrum, J ) 12 Hz, H2C-Ar), 3.50 and 3.35 (2H, AB
spectrum, J ) 11.8 Hz, H2C-Ar), 3.30-2.30 (9H, m, H
piperazine and H2C-Cl).
1,4-Dibenzyl-2-(cyanomethyl)piperazine (38). To a re-
fluxing solution of KCN (4.57 g, 0.07 mol) in water (20 mL)
was added dropwise the halide 37 (17 g, 0.054 mol) in ethanol
(20 mL). The mixture was stirred and refluxed for 3 h. Ethanol
was evaporated, the residue was taken up in chloroform,
washed with water, and dried over MgSO4, and the solvent
was removed in vacuo. Crystallization from hexane/ether gave
13.2 g (80%) of 38 as a white powder: mp 80-89 °C; IR (film,
cm-1) î 2215 (CN), 1600 (CdC); 1H NMR ä 7.21 (10H, br s,
Ar-H), 3.72 and 3.40 (2H, AB spectrum, J ) 13.5 Hz, H2C-
Ar), 3.45 (2H, s, H2C-Ar), 3.00-2.10 (9H, m, H piperazine and
H2C-CN).
Ethyl 1,4-Dibenzylpiperazin-2-ylacetate (39). A mixture
of 13.2 g (0.043 mol) of 38, H2SO4 (10 mL at 95%), and ethanol
(30 mL) was stirred and refluxed for 3 h. Then ethanol was
evaporated, and the residue was taken up in chloroform,
washed with water, and dried over MgSO4. Evaporation of the
organic layer gave a crude product which was purified by
column chromatography using petroleum ether/ether (90:10,
v/v) as eluent to give 11.4 g (75%) of 38 as a yellow oil: IR
(film, cm-1) î 1720 (CdO), 1600 (CdC); 1H NMR ä 7.23-7.14
(10H, m, Ar-H), 4.07 (2H, dq, J ) 6.95 and 3.25 Hz, H2C-O),
3.72 and 3.34 (2H, AB spectrum, J ) 13.3 Hz, H2C-Ar), 3.47
and 3.38 (2H, AB spectrum, J ) 13.1 Hz, H2C-Ar), 3.07-3.02
(1H, m, HC-N), 2.60 and 2.22 (8H, m, three H2C-N and H2C-
CdO), 1.15 (3H, t, J ) 7.10 Hz, H3C-CH2O).
Ethyl Piperazin-2-ylacetate Dihydrochloride (40). To
a solution of 39 (20 g, 0.057 mol) in ethanol (200 mL) were
added concentrated HCl (9 mL) and 10% palladium on
charcoal. The mixture was kept under H2 atmosphere for 5 h
at 50 °C. The catalyst was filtered and the solvent removed in
vacuo. The crude product 40 was used in the next step without
purification.
Ethyl 1,4-diisopropylpiperazin-2-ylacetate (40a): pre-
pared like 2a starting from 40; 1H NMR ä 4.07 (2H, q, J )
7.13 Hz, H2C-O), 3.16-2.28 (11H, m, H piperazine, H2C-CO2,
two HC(CH3)2), 1.22-0.90 (15H, m, H3C-CH2O, two (H3C)2-
CH, H3C signals overlapping).
Ethyl 1-(2′,4′-dichlorobenzyl)-4-methylpiperazin-2-
ylacetate (40b) and ethyl 1-(2′-methoxybenzyl)-4-meth-
ylpiperazin-2-ylacetate (40c): prepared like 7b; 1H NMR ä
7.38-7.11 (3H, m, H-Ar), 4.06 (2H, q, J ) 7.09 Hz, H2C-O),
3.75 and 3.44 (2H, AB spectrum, J ) 14.76 Hz, H2C-Ar), 3.6-
2.19 (9H, m, H piperazine and H2C-CO2), 2.24 (3H, s, H3C-
N), 1.16 (3H, t, J ) 7.09 Hz, H3C-CH2O). 1H NMR spectrum
of 40c was similar to the one of compound 40b; particular
signal ä 3.69 (3H, s, H3C-O).
Preparation of Final Imidazoline (41a-q, 42, 60-63)
and Tetrahydropyrimidine (43) Analogues (Scheme 5).
The compounds 41a-q, 42, and 60-63 were prepared as
described in our previous publication16 using the corresponding
esters. All the 1H NMR spectra were recorded from the free
bases. The hydrogens of the imidazoline ring of compounds
41a, 41b, 41d, 41e, 41g, 41n, 41j, 41l, and 41m gave
unresolved peaks. The corresponding signal is very broad, and
the summit of this signal was a coalescence point.
1,4-Diisopropyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)pip-
erazine (41a): 1H NMR ä 5.3 (1H, br s, D2O exchange, H-N),
3.52 (1H, dd, J ) 3.37 and 7.91 Hz, HC-N), 3.65 and 3.49
(4H, 2 coalescence points, H imidazoline), 2.83-2.26 (8H, m,
three H2C-N and two HC(CH3)2), 1.00, 0.96, 0.95 and 0.93
(12H, 4d, J ) 6.35 and 6 Hz, two (H3C)2CH). 41aâ1.5HCl: 35%
yield; mp 145-147 °C (acetone/ether). Anal. (C13H26N4â3HClâ
1.5H2O) C, H, N.
1,4-Diisobutyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)pip-
erazine (41b): 1H NMR ä 5.45 (1H, br s, D2O exchange,
H-N), 3.53-3.47 (4H, m, H imidazoline), 3.20 (1H, dd, J )
3.32 and 7.01 Hz, HC-N), 2.82-1.93 (10 H, m, three H2C-N
and two H2C-CH), 1.81-1.62 (2H, m, two HC(CH3)2), 0.61, 0.79
and 0.77 (12H, 3d in 2:1:1 ratio, J ) 6.29 Hz, two (H3C)2CH).
41bâ3HCl: 33% yield; mp 152-154 °C (acetone/CH2Cl2). Anal.
(C15H30N4â3HClâ0.75H2O) C, H, N.
1,4-Dicyclopentyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-
piperazine (41c): 1H NMR ä 5.1 (1H, br s, D2O exchange,
H-N), 3.61-3.49, 2.77-2.35 and 2.00-1.19 (29H, 3m in 5:8:
16 ratio). 41câ3HCl: 29% yield; mp 159-161 °C. Anal.
(C17H30N4â3HClâ0.5H2O) C, H, N.
1,4-Di(2′-propen-1′-yl)-2-(4′,5′-dihydro-1′H-imidazol-2′-
yl)piperazine (41d): 20% yield; mp 102-104 °C (hexane);
1H NMR ä 5.85-5.64 (2H, m, two HCd), 5.17-5.06 (5H, m,
two H2Cd and H-N′), 3.50 (4H, coalescence point, H imida-
zoline), 3.27 (1H, dd, J ) 3.20 and 8.45 Hz, HC-N), 3.15-
2.17 (10H, m, three H2C-N and two H2C-Cd). Anal. (C13H22N4)
C, H, N.
1,4-Di(2′-methyl-2′-propen-1′-yl)-2-(4′,5′-dihydro-1′H-
imidazol-2′-yl)piperazine (41e): 30% yield; mp 83-84 °C
(hexane); 1H NMR ä 5.2 (1H, br s, D2O exchange, H-N), 4.84-
4.78 (4H, m, two H2Cd), 3.50 (4H, coalescence point, H
imidazoline), 3.24 (1H, dd, J ) 3.2 and 7.96 Hz, HC-N), 2.91-
1.64 (10H, m, three H2C-N and two H2C-Cd), 1.65 and 1.64
(6H, 2s, two H3C-Cd). Anal. (C15H26N4) C, H, N.
1,4-Di(2′-methylbutyl)-2-(4′,5′-dihydro-1′H-imidazol-2′-
yl)piperazine (41f): 1H NMR ä 5.20 (1H, br s, H-N), 3.50-
3.46 and 3.26-3.19 (4H, 2m, H imdazoline), 2.91-2.90 (11H,
m, H piperazine and two H2C-CH), 1.56-0.94 (6H, m, two
H2C-CH3 and two HC(CH3), 0.85-0.74 (12H, m, two H3C-
CH2 and two H3C-CH, H3C signals overlapping). 41fâ3HCl:
30% yield; mp 160 °C dec (MeOH/acetone). Anal. (C17H34N4â
3HClâ0.25H2O) C, H, N.
1,4-Dineopentyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)pip-
erazine (41g): 1H NMR ä 5.3 (1H, br s, D2O exchange, H-N),
3.60 and 3.35 (4H, coalescence point, H imidazoline), 3.3 (1H,
dd, J1 ) J2 ) 3.88 Hz, HC-N), 3.08-3.10 and 2.75-2.30 (7H,
2m, three H2C-N and H-CH-C(CH3)3), 2.05 (2H, s, H2C-
C(CH3)3), 1.93 (1H, d, part B of AB spectrum, J ) 14.93 Hz,
H-CH-C(CH3)3), 0.85 (18H, br s, two (H3C)3-C). 41gâ2HCl:
25% yield; mp 178 °C dec (CH2Cl2/MeOH/hexane). Anal.
(C17H34N4â2HClâ2H2O) C, H, N.
1,4-Bis(dicyclopropylmethyl)-2-(4′,5′-dihydro-1′H-imi-
dazol-2′-yl)piperazine (41h): 58% yield; mp 156 °C (CH2-
Cl2/ether); 1H NMR ä 5.6 (1H, br s, D2O exchange, H-N), 3.90
(1H, dd, J ) 3.37 and 7.0 Hz, HC-N), 3.50 (4H, coalescence
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point, H imidazoline), 3.16-2.52 (6H, m, three H2C-N), 1.39
and 1.05 (2H, 2t, J ) 8.3 and 8.5 Hz, two HC-dicyclopropyl),
0.97-0.10 (10H, m, H cyclopropyl). Anal. (C21H34N4) C, H, N.
1-Isobutyl-4-(2′-propen-1′-yl)-2-(4′,5′-dihydro-1′H-imi-
dazol-2′-yl)piperazine (41i): 29% yield; mp 96-98 °C (hex-
ane); 1H NMR ä 5.86-5.66 (1H, m, HCd), 5.3 (1H, br s, D2O
exchange, H-N), 5.15-5.06 (2H, m, H2Cd), 3.49 (4H, coales-
cence point, H imidazoline), 3.16 (1H, dd, J ) 3.24 and 8.80
Hz, HC-N), 3.00-2.61 and 2.26-1.93 (10H, 2m, three H2C-
N, H2C-CH and H2C-Cd), 1.82-1.68 (1H, m, HC(CH3)2), 0.81
and 0.78 (6H, 2d, J ) 6.5 Hz, (H3C)2CH). Anal. (C14H26N4â0.25
H2O) C, H, N.
1-Isobutyl-4-(2′-methyl-2′-propen-1′-yl)-2-(4′,5′-dihydro-
1′H-imidazol-2′-yl)piperazine (41j): 30% yield; mp 104-
106 °C (hexane); 1H NMR ä 5.2 (1H, br s, D2O exchange, H-N),
4.78 (2H, s, H2Cd), 3.50 (4H, coalescence point, H imidazoline),
3.20 (1H, dd, J ) 3.30 and 7.82 Hz, HC-N), 2.84-1.65 (11H,
m, three H2C-N, H2C-CH, H2C-Cd and HC(CH3)2), 0.81 and
0.78 (6H, 2d, J ) 6.2 Hz, (H3C)2CH). Anal. (C15H28N4) C, H,
N.
1-Methyl-4-isobutyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-
piperazine (41k): 1H NMR ä 4.55 (1H, br s, D2O exchange,
H-N), 3.60 (4H, br s, H imidazoline), 3.50-2.00 (10H, m, H
piperazine, H2C-CH, HC(CH3)2), 2.25 (3H, s, H3C-N). 41kâ
3HCl: 40% yield; mp 142 °C dec (acetone). Anal. (C12H24N4â
3HClâH2O) C, H, N.
1-Isobutyl-4-methyl-2-(4′,5′-dihydro-1′H-imidazol-2′-
yl)piperazine (41l): 1H NMR ä 5.0 (1H, br s, D2O exchange,
H-N), 3.50 (4H, coalescence point, H imidazoline), 3.25 (1H,
dd, J ) 3.25 and 7.80 Hz, HC-N), 2.80-2.0 (8H, three H2C-N
and H2C-CH), 1.80-1.65 (1H, m, HC(CH3)2), 0.80 and 0.78
(6H, 2d, J ) 6.3 Hz, (H3C)2CH). 41lâ2HCl: 38% yield; mp
137.5-139 °C. Anal. (C12H24N4â2HClâH2O) C, H, N.
1-(Dicyclopropylmethyl)-4-methyl-2-(4′,5′-dihydro-1′H-
imidazol-2′yl)piperazine (41m): 50% yield; mp 96-98 °C
(ethanol/acetone); 1H NMR ä 5.0 (1H, br s, D2O exchange,
H-N), 3.88 (1H, dd, J ) 3.31 and 9.1 Hz, HC-N), 3.46 (4H,
coalescence point, H imidazoline), 3.06-2.97, 2.87-2.59 and
2.2-2.05 (6H, 3m, H2C-N), 2.2 (3H, s, H3C-N), 1.32 (1H, t, J
) 8.36 Hz, HC-dicyclopropyl), 0.88-0.05 (10H, m, H cyclopro-
pyl). Anal. (C15H26N4) C, H, N.
1-Phenyl-4-methyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-
piperazine (41n): 10% yield; mp 106-108 °C (hexane); 1H
NMR ä 7.23-7.16, 6.97-6.93 and 6.83-6.76 (5H, 3m, Ar-H),
4.41 (1H, dd, J 1 ) J2 ) 4.0 Hz, HC-N), 3.40 (4H, br s, H
imidazoline), 3.33-3.27, 2.87-2.79, 2.71-2.64, 2.57-2.49 and
2.37-2.31 (6H, 5m, three H2C-N), 2.23 (3H, s, H3C-N). Anal.
(C14H20N4) C, H, N.
1-Isopropyl-4-phenyl-2-(4′,5′-dihydro-1′H-imidazol-2′-
yl)piperazine (41o): 25% yield; mp 98-100 °C (ether/
hexane); 1H NMR ä 7.22-7.06 and 6.87-6.75 (5H, 2m, Ar-
H), 4.25 (1H, br s, D2O exchange, H-N), 3.66-3.35, 2.93-2.76
and 2.59-2.47 (12H, 3m, H imidazoline, H piperazine and HC-
(CH3)2), 1.05 and 0.93 (6H, 2d, J ) 6.53 Hz, (H3C)2CH). Anal.
(C14H24N4) C, H, N.
1-Methyl-4-(2′-chlorophenyl)-2-(4′,5′-dihydro-1′H-imi-
dazol-2′-yl)piperazine (41p): 12% yield; mp (free base) 115-
117 °C (acetone/ether); 1H NMR ä 7.32-6.90 (4H, m, Ar-H),
4.25 (1H, br s, D2O exchange, H-N), 3.54 (4H, br s, H
imidazoline), 3.36-3.26, 3.06-2.88 and 2.60-2.51 (7H, 3m, H
piperazine), 2.27 (3H, s, H3C-N). Anal. (C14H19ClN4) C, H, N.
1-Phenyl-4-isopropyl-2-(4′,5′-dihydro-1′H-imidazol-2′-
yl)piperazine (41q): 15% yield; mp 120-122 °C (acetone/
ether); 1H NMR ä 7.22-7.14, 7.0-6.96 and 6.82-6.74 (5H, 3m,
Ar-H), 4.99 (1H, br s, D2O exchange, H-N), 4.41 (1H, dd, J1
) J2 ) 4.02 Hz, HC-N), 3.36 (4H, s, H imidazoline), 3.31-
3.26 and 2.84-2.67 (6H, 2m, three H2C-N), 2.63-2.47 (1H,
m, HC(CH3)2), 1.02 and 1.01 (6H, 2d, J ) 6.5 Hz, (H3C)2CH).
Anal. (C16H24N4) C, H, N.
1-(2′,4′-Dichlorobenzyl)-4-methyl-2-(4′,5′-dihydro-1′-
methylimidazol-2′-yl)piperazine (42): 1H NMR ä 7.52-7.0
(3H, m, Ar-H), 3.9-2.0 (13H, m, H2C-Ar, H piperazine and
H imidazoline), 2.95 (3H, s, H3C-N-Cd), 2.27 (3H, s, H3C-
N). 42â3HCl: 40% yield; mp 160-162 °C (acetone/ethanol).
Anal. (C16H22Cl2N4â3HClâ2.5H2O) C, H, N.
1-(2′,4′-Dichlorobenzyl)-4-methyl-2-(1′,4′,5′,6′-tetrahy-
dro-1′H-pyrimidin-2′-yl)piperazine (43): 1H NMR ä 7.29-
7.19 (3H, m, Ar-H), 5.52 (1H, br s, H-N), 3.68-3.40, 2.80-
2.10 and 1.89-1.68 (15H, 3m, H2C-Ar, H piperazine and H
tetrahydropyrimidine), 2.25 (3H, s, H3C-N). 43â3HCl: 39%
yield; mp 175-177 °C (methanol/acetone). Anal. (C16H22Cl2N4â
3HClâH2O) C, H, N.
1,4-Diisopropyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-
methylpiperazine (60): 32% yield; mp 197 °C (hexane/
ether); 1H NMR ä 4.45 (2H, br s, D2O exchange, H-N and 0.5
H2O), 3.53-2.03 (15H, m, H imidazoline, H piperazine, two
HC(CH3)2 and H2C-CdN), 1.06, 0.96 and 0.88 (12H, 3d in
1:2:1 ratio, J ) 6.50 Hz, two (H3C)2CH). Anal. (C14 H28N4â3HClâ
3H2O) C, H, N.
1,4-Dibenzyl-2-(4′,5′-dihydro-1′H-imidazol-2′-yl)-meth-
ylpiperazine (61): 1H NMR ä 7.35-7.15 (10H, m, Ar-H),
3.95 (1H, part A of AB spectrum, J ) 12.7 Hz, HCH-Ar),
3.55-3.20 (7H, m, H imidazoline, H2C-Ar and HCH-Ar),
2.85-2.10 (9H, m, H piperazine, H2C-CdN). 61â3HCl: 70%
yield; mp 176-178 °C (ether/hexane). Anal. (C22H28N4â3HClâ
2H2O) C, H, N.
1-(2′-Methoxybenzyl)-4-methyl-2-(4′,5′-dihydro-1′H-imi-
dazol-2′-yl)methylpiperazine (62): 1H NMR spectrum simi-
lar to compound 61, particular signal ä 3.88 (3H, s, H3C-O).
62â3HCl: 40% yield; mp 160-162 °C (ethanol/acetone). Anal.
(C17H26N4Oâ3HClâ2H2O) C, H, N.
1-(2′,4′-Dichlorobenzyl)-4-methyl-2-(4′,5′-dihydro-1′H-
imidazol-2′-yl)methylpiperazine (63): 1H NMR ä 7.35-
7.13 (3H, m, Ar-H), 3.88 and 3.48 (2H, AB spectrum, J ) 14.2
Hz, H2C-Ar), 3.47 (4H, br s, H imdazoline), 2.86-2.2 (9H, m,
H piperazine, H2C-CdN), 2.17 (3H, s, H3C-N). 63â2HCl: 70%
yield; mp 160-162 °C (ether/hexane). Anal. (C16H22Cl2N4â
2HClâH2O) C, H, N.
Preparation of Oxazoline Analogue 50 (Scheme 6).
N,N-Dibenzylethanolamine Hydrochloride (44). To 18 mL
(0.3 mol) of ethanolamine in absolute EtOH (400 mL) and Et3N
(100 mL) was added 69 mL (0.6 mol) of benzyl chloride in
absolute EtOH (70 mL). The solution was refluxed overnight;
then the ethanol was evaporated and the residue taken up in
a saturated Na2CO3 solution and ether. The organic layer was
washed with diluted HCl; the aqueous layer was neutralized
with Na2CO3 and extracted with ether. After drying over
MgSO4 the solvent was evaporated and the residue purified
by crystallization of the hydrochloride salt from ethanol/ether
to afford 46 g (55%) of 44 as a white powder: mp 149.5 °C; IR
(film, cm-1) î 3550-3525 (OH), 1599 (CdC); 1H NMR ä 7.30-
7.01 (10H, m, Ar-H), 3.68 (4H, s, two H2C-Ar), 3.50 (1H, s,
D2O exchange, H-O), 3.45 (2H, t, J ) 6.8 Hz, H2C-O), 2.54
(2H, t, J ) 6.8 Hz, H2C-N).
Tetrahydropyran-2-yloxyethylamine (46). A total of 50
mL (0.56 mol) of dihydropyran was added dropwise to 78 g
(0.28 mol) of 44 in CH2Cl2 (500 mL). The solution was stirred
at room temperature for 2 days and then poured into a molar
solution of Na2CO3 (300 mL). The aqueous layer was extracted
with CH2Cl2. The organic layer was dried over MgSO4 and
concentrated to give 45 which was used in the next step
without purification. A shaken suspension of 10% Pd/C (300
mg) and 45 (50 g, 0.21 mol) in anhydrous ethanol (300 mL)
was kept under an H2 atmosphere for 12 h at room temper-
ature. The solution was filtered through Celite, and the filtrate
was concentrated. The crude 46 was purified by distillation
(E15 ) 102-104 °C) to give 32 g (79%) of the title compound:
IR (KBr, cm-1) î 3380-3369 (NH); 1H NMR ä 4.53 (1H, t, J )
3.19 Hz, HC-O), 3.84-3.63 and 3.47-3.30 (4H, 2m, two H2C-
O), 2.79 (2H, t, J ) 5.32 Hz, H2C-N), 2.02 (2H, br s, D2O
exchange, H2N), 1.78-1.46 (6H, m, H2C-C).
1-(2′-Chlorobenzyl)-4-methyl-2-[((tetrahydropyran-2-
yloxy)ethylamino)carbonyl]piperazine (47). 46 (7.3 g, 0.05
mol) in toluene (25 mL) was added dropwise to a stirred and
cooled solution of 25 mL of Al(CH3)2 (0.05 mol) in toluene at 0
°C, so that the temperature did not exceed 10 °C. After 1 h,
10 g (0.038 mol) of 7c dissolved in toluene (20 mL) was added
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gradually at room temperature. The reaction mixture was
refluxed for 4 h (argon atmosphere) and stirred one night at
room temperature. The mixture was then cooled again and
treated dropwise with 100 mL of water/MeOH (20:80, v/v).
After filtration and solvent evaporation, the residue was
suspended in methylene chloride (200 mL). The organic layer
was washed with water and dried over MgSO4 and the solvent
removed in vacuo. The crude product 47 was used in the next
step without purification.
1-(2′-Chlorobenzyl)-4-methyl-2-[(hydroxyethylamino)-
carbonyl]piperazine (48). 47 (11 g) was solubilized in MeOH
saturated with HCl (75 mL) and stirred for 2 h. The solvent
was removed in vacuo, and the residue was taken up in water.
The aqueous solution was extracted with CH2Cl2 and then
neutralized with Na2CO3. The organic layer was dried over
MgSO4 and concentrated to afford 7.3 g (62%) of 48: IR (film,
cm-1) î 3400 (NH and OH), 1660 (CdO); 1H NMR ä 7.66 (1H,
br s, D2O exchange, H-N), 7.38-7.11 (4H, ma, Ar-H), 3.80
and 3.48 (2H, AB spectrum, J ) 13.9 Hz, H2C-Ar), 3.70-3.55
(2H, m, H2C-O), 3.38-3.33 (2H, m, H2C-N-CdO), 3.15 (1H,
dd, J ) 3.6 and 8 Hz, HC-N), 2.89-2.70 and 2.51-2.11 (6H,
2m, three H2C-N), 2.21 (3H, s, H3C-N), 1.87 (1H, br s, D2O
exchange, H-O).
1-(2′-Chlorobenzyl)-4-methyl-2-[(chloroethylamino)-
carbonyl]piperazine (49). To 48 (7 g, 0.022 mol) in ice bath-
cooled chloroform (50 mL) was added dropwise 2.7 mL (0.037
mol) of freshly distilled thionyl chloride in CHCl3 (10 mL). The
mixture was stirred 12 h in ice bath and then poured in a
molar solution of Na2CO3 (60 mL). The organic layer was dried
over MgSO4 and concentrated. The crude product was purified
by column chromatography using ether/petroleum ether (50:
50, v/v) as eluent to give 4.5 g (61%) of 49 as white crystals:
mp 74-75 °C; IR (KBr, cm-1) î 3300 (NH, OH), 1670 (CdO),
1600 (CdC); 1H NMR ä 7.80 (1H, s, HN-CdO), 7.38-7.10 (4H,
m, Ar-H), 3.70 and 3.55 (2H, AB spectrum, J ) 14.5 Hz, H2C-
Ar), 3.54 (4H, s, H2C-N-CdO and H2C-Cl), 3.18-3.10, 2.82-
2.69 and 2.50-2.20 (7H, 3m, H piperazine), 2.23 (3H, s, H3C-
N).
1-(2′-Chlorobenzyl)-4-methyl-2-(4′,5′-dihydro-1′,3′-oxazol-
2′-yl)piperazine (50). To 2.2 g (6.7 mmol) of 49 in EtOH (15
mL) was added rapidly 0.26 g (6.5 mmol) of NaOH in hot EtOH
at 80% (6 mL). The mixture was stirred overnight at room
temperature, then filtered, and concentrated. The residue was
taken up in ether and washed with water. The organic layer
was dried over MgSO4 and the ether removed in vacuo; 1.7 g
(85%) of 51 as white crystals was obtained after addition of
hexane: mp 97 °C; IR (KBr, cm-1) î 1680 (CdN), 1590 (CdC)
cm-1; 1H NMR ä 7.41-7.46 and 7.35-7.05 (4H, 2m, Ar-H),
4.25-4.03 and 3.88-3.72 (4H, 2m, H oxazoline), 3.76 and 3.64
(2H, AB spectrum, J ) 17 Hz, H2C-Ar), 3.43 (1H, dd, J ) 3.5
and 8.5 Hz, HC-N), 2.93-2.82, 2.72-2.65 and 2.54-2.21 (6H,
3m, three H2C-N), 2.21 (3H, s, H3C-N). Anal. (C15 H20ClN3O)
C, H, N.
Preparation of Amidine Analogues 52a, 52b, and 56
(Scheme 7). 1,4-Dibenzyl-2-cyanopiperazine Dihydro-
chloride (51). To a hot (80 °C) stirred solution of N,N′-
dibenzylethylenediamine (72 g, 0.3 mol) and triethylamine
(100 mL, 0.72 mol) in toluene (300 mL) was added dropwise,
but rapidly, freshly distilled 2,3-dibromopropionitrile (70 g, 0.3
mol) in toluene (300 mL). After the addition, the reaction
mixture was stirred at 80 °C for 3 h, then cooled, and filtered.
The filtrate was washed with saturated aqueous NaHCO3 (200
mL). The organic layer was dried over MgSO4 and the solvent
removed in vacuo. The crude product was dissolved in anhy-
drous EtOH (400 mL) and saturated with HCl gas. The
addition of ether gave a precipitate of 51 (65.5 g, 60%) as a
white powder: mp 152-154 °C; IR (free base, film, cm-1) î
2200 (CN), 1600 (CdC); 1H NMR ä 7.40-7.10 (10H, m, Ar-
H), 3.38-3.88 (4H, m, H2C-Ar), 3.32-3.21, 3.05-2.95 and
2.69-2.27 (7H, 3m, H piperazine).
1,4-Dibenzyl-2-amidinopiperazine Hydrochloride (52a).
A total of 50 mL of a solution of Al(CH3)3 (2 M) in toluene was
added dropwise to a cold and stirred suspension of NH4Cl (5.35
g, 0.1 mol) in 50 mL of toluene according to Levin et al.
procedure.25 The mixture was stirred 1 h at room temperature;
then 10 g (0.034 mol) of 51 dissolved in toluene (50 mL) was
added dropwise. The solution was heated at 80-90 °C over-
night. After cooling in an ice bath, MeOH/H2O (80:20, v/v) was
added carefully and the mixture filtered. The salts were
washed with CHCl3, and the filtrate was acidified. The solvents
were evaporated to dryness; the residue was taken up in CHCl3
and filtered again. After evaporation of CHCl3, the crude
product was purified by column chromatography using CHCl3/
MeOH (95: 5, v/v) as eluent to give 4.2 g (36%) of 52a as a
white powder: mp 175-177 °C (CH2Cl2/ether); IR (film, cm-1)
î 3420-3390 (NH), 1615 (CdN), 1595 (CdC); 1H NMR (free
base) ä 7.28-7.13 (10H, m, Ar-H), 4.56 (5H, br s, D2O
exchange, H2N, HNd and 1H2O), 3.77 and 3.18 (2H, AB
spectrum, J ) 13.37 Hz, H2C-Ar), 3.39 (2H, s, H2C-Ar), 3.05
(1H, dd, J ) 3.3 and 8.7 Hz, HC-N), 2.85-2.51 and 2.32-
2.10 (6H, 2m, three H2C-N). Anal. (C19H24N4â0.75HCl) C, H,
N.
1,4-Dibenzyl-2-(N-methylamidino)piperazine Hydro-
chloride (52b). It was prepared by the same procedure as
above using the corresponding nitrile 51 derivative and
methylamine hydrochloride salt: 52%; mp 221-223 °C dec
(CH2Cl2/acetone); this compound gave 1H NMR spectrum
similar to that of 52a, particular signal ä ppm 2.31 (3H, s,
H3C-Nd). Anal. (C20H26N4â1HCl) C, H, N.
N,N′-Dibenzyl-N,N′-diisopropylethylenediamine (53).
A total of 38 g (0.223 mol) of isopropyl iodide was added to a
suspension of 24 g (0.1 mol) of N,N′-dibenzylethylenediamine
and 35 g of dry K2CO3 in 100 mL of acetonitrile. The reaction
mixture was refluxed for 48 h. After cooling and filtration, the
solvent was removed in vacuo. The residue was dissolved in
CH2Cl2, the solution washed with water and then dried over
MgSO4, and the solvent evaporated. The crude product was
purified by column chromatography using petroleum ether/
ether (80:20, 70:30 then 50:50, v/v) as eluent to give 29 g (89%)
of 53 as a colorless oil: IR (film, cm-1) î 1590 (CdC); 1H NMR
ä 7.25-7.09 (10H, m, Ar-H), 3.44 (4H, s, two H2C-Ar), 2.88-
2.70 (2H, m, two HC(CH3)2), 2.33 (4H, s, two H2C-N), 0.87
(12H, d, J ) 6.6 Hz, two (H3C)2CH).
N,N′-Diisopropylethylenediamine (54). The procedure
was the same as the one used for the preparation of 17 starting
from 28 g (0.086 mol) of 53. The crude product was purified
by distillation (E15 ) 60 °C) yielding 9 g (70%) of 54 as a
colorless oil: IR (film, cm-1) î 3300 (NH), 1590 (CdC); 1H NMR
ä 2.89 (1H, br s, D2O exchange, two HN), 2.80 (2H, sept, J )
6.3 Hz, two HC-(CH3)2), 2.73 (4H, s, two H2C-N), 1.05 (12H,
d, J ) 6.4 Hz, two (H3C)2CH).
1,4-Diisopropyl-2-cyanopiperazine (55). The procedure
was the same as for the preparation of 51 using 7 g (0.05 mol)
of 54. The crude product was purified by distillation (E0.05 )
76-82 °C) yielding 5 g (51%) of 55 as a yellow oil: IR (film,
cm-1) î 2200 (CdN); 1H NMR ä 3.90 (1H, br s, HC-N), 2.91-
2.25 (8H, m, three H2C-N and two HC(CH3)2), 1.09-0.92 (12H,
m, two (H3C)2CH, the CH3 groups were nonequivalents and
the doublets overlapped).
1,4-Diisopropyl-2-(N-methylamidino)piperazine hy-
drochloride (56): 55%; mp 208-210 °C (acetone); 1H NMR
ä 5.65 (4H, br s, D2O exchange, H-N, HNd and 1H2O), 3.54
(1H, dd, J ) 3.30 and 7.44 Hz, HC-N), 2.92 (3H, s, H3C-N),
2.97-2.27 (8H, m, three H2C-N and two HC(CH3)2), 0.99, 0.95
and 0.86 (2H, 3d in 1:2:1 ratio, J ) 7.0 and 6.54 Hz, two
(H3C)2-CH). Anal. (C12H26N4â2HCl) C, H, N.
Preparation of Imidazole Analogue 56 (Scheme 8).
1-(2′,4′-Dichlorobenzyl)-4-methyl-2-(hydroxymethyl)pip-
erazine (57). This compound was prepared from ethyl 1-(2′,4′-
dichlorobenzyl)-4-methylpiperazine-2-carboxylate16 using the
same procedure as for derivative 36: IR (film, cm-1) î 3400
(OH), 1600 (CdC); 1H NMR ä 7.50-7.05 (3H, m, Ar-H), 5.20
(1H, br s, D2O exchange, H-O), 4.20-3.40 (5H, m, H2C-Ar,
H2C-O and HC-N), 3.05-2.30 (6H, m, three H2C-N), 2.20
(3H, s, H3C-N).
1-(2′,4′-Dichlorobenzyl)-4-methyl-2-formylpiperazine
(58). To a solution of DMSO (20 mL) in dry CH2Cl2 (140 mL)
was added dropwise for 10 min at -60 °C freshly distilled
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oxalyl chloride (30 mL) in dry CH2Cl2 (60 mL) with stirring
under nitrogen atmosphere. After 15 min, 15 g of 57 in dry
CH2Cl2 (250 mL) was added dropwise to the solution mixture
while the temperature was maintained at -60 °C. After
stirring 90 min, triethylamine (56 mL) was added quickly and
the reaction mixture was allowed to warm to -30 °C. After
stirring for 2 h, the solution mixture was allowed to warm to
room temperature and concentrated. The residue was taken
up in chloroform; the organic layer was washed with water
and dried over MgSO4. After evaporation the residue was
purified by column chromatography using ether as eluent to
afford 58 as a viscous oil (6.76 g, 35%): IR (film, cm-1) î 1740
(CdO), 1600 (CdC); 1H NMR ä 9.70 (1H, d, J ) 2.4 Hz, HCd
O), 7.45-7.10 (3H, m, Ar-H), 3.90 and 3.82 (2H, AB spectrum,
J ) 14 Hz, H2C-Ar), 3.55-2.12 (7H, m, H piperazine), 2.20
(3H, s, H3C-N).
1-(2′,4′-Dichlorobenzyl)-4-methyl-2-(imidazol-2′-yl)pip-
erazine (59). To a stirred solution of 58 (5.5 g, 0.019 mol)
and glyoxal (2 g) in MeOH (100 mL) was added dropwise
anhydrous ammonia at -10 °C. This temperature was main-
tained for 2 h; then the solution was allowed to warm to room
temperature. The addition of water (200 mL) gave a precipitate
of 59 as a white powder (3.41 g, 55%): mp (free base)152-
154 °C; 1H NMR ä 10.95 (1H, br s, D2O exchange, H-N), 7.45-
7.02 (3H, m, Ar-H), 6.95 (2H, s, two HCd), 3.98 (1H, t, J )
3.7 Hz, HC-N), 3.63 and 3.16 (2H, AB spectrum, J ) 13.7
Hz, H2C-Ar), 2.71-2.30 (6H, m, three H2C-N), 2.24 (3H, s,
H3C-N). Anal. (C15H18Cl2N4â2HCl) C, H, N.
Pharmacology. Animals and Treatments. Three month-
old male Wistar rats (Iffa-Credo, France) weighing about 250
g were used in all the experiments. The animals were housed
in wire-bottomed cages and maintained at 21 ( 2 °C in a room
with a 12-h fixed light-dark schedule. Water and standard
laboratory chow (UAR, Villemoison-sur-Orge, France) were
freely available.
Moderate diabetes were obtained by a single iv injection of
a low dose (35 mg/kg) of streptozotocin (STZ) dissolved in a
citrate buffer28 under ketamine hydrochloride anesthesia (75
mg/kg ip; Imalgene, Me´rieux, France). These rats were called
STZ rats. Control rats received an injection of the vehicle under
the same conditions.
Glucose homeostasis and insulin secretion were assessed by
glucose tolerance tests performed 2 weeks after STZ injection.
Intravenous Glucose Tolerance Tests (IVGTT). Glucose
was dissolved in 0.9% saline and given by the saphenous vein
route (0.5 g/kg) in rats under pentobarbital anesthesia (60 mg/
kg ip; Clin-Midy, France). Blood samples were collected
sequentially from the tail vessels before and 5, 10, 15, 20, and
30 min after the injection of glucose. They were then centri-
fuged, and the plasma was separated. Plasma glucose concen-
tration was immediately determined in a 10-íL aliquot, and
the plasma left was kept at -20 °C until radioimmunoassay
of insulin.
Drug Administration and Antidiabetic Activity. The
2-(4′,5′-dihydro-1′H-imidazol-2′-yl)piperazine derivatives were
tested by a single ip injection of 100 ímol/kg in the STZ rat
20 min before the IVGTT. All the compounds were used in
the form of hydrochloride salts and were water-soluble. An-
tidiabetic activity of the compounds was evaluated using two
parameters: ¢G, which represents the increase in glycemia
over baseline integrated over a period of 30 min (IVGTT)
following the glucose load, and K, which is the rate of glucose
disappearance between 5 and 30 min (in the case of IVGTT),
after glucose administration. The K coefficient was calculated
only during IVGTT.
Tissue and Membrane Preparation. Cerebral cortex was
obtained from whole bovine brains and homogenized in 20
volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4). The
homogenate was centrifuged twice at 48000g for 25 min at 4
°C. The pellet (used for R2 binding assays) was resuspended
in a phosphate buffer (pH 7.4), flash-frozen, and stored at -80
°C until R2 binding assays.
Reticular nucleus from calf’s bulbis was homogenized in ice-
cold 50 mM Tris-HCl buffer (pH 7.7) containing 5 mM EDTA.
The homogenate was centrifuged at 500g for 10 min at 4 °C.
The pellet (P1) was resuspended in the same buffer and
centrifuged again. The combined supernatants were centri-
fuged at 50000g for 25 min at 4 °C. The resulting pellet (P2)
was resuspended in 50 mM Tris-HCl buffer (pH 7.7) containing
0.1 mM p-methanesulfonyl fluoride, incubated for 30 min at
25 °C, then centrifuged again in the same conditions, resus-
pended in 50 mM Tris-HCl (pH 7.7), flash-frozen, and stored
at -80 °C until I1-imidazoline binding assays.
Renal cortex was obtained from male New Zealand white
rabbits and homogenized in ice-cold preparation buffer (20 mM
NaHCO3).42 The homogenate was centrifuged at 40000g for
30 min at 4 °C. The pellet was resuspended in 50 mM Tris-
HCl buffer containing 0.5 mM EDTA (pH 7.4), centrifuged
again, resuspended in the same buffer, flash-frozen, and stored
at -80 °C until I2-imidazoline binding assays.
Binding Assays. [3H]RX 821002 (48 Ci/mmol), [3H]-p-
aminoclonidine (50 Ci/mmol), and [3H]idazoxan (42 Ci/mmol)
were obtained from Amersham (Buckinghamshire, U.K.), and
phentolamine, guanabenz, tolazoline, idazoxan, yohimbine,
clonidine, naphazoline, and amiloride were from Sigma (St
Louis, MO). Radioligand binding assays with [3H]RX 821002,
[3H]-p-aminoclonidine, or [3H]idazoxan for determination of
specific binding to R2 adrenoceptors, I1-PBS, and I2-PBS,
respectively, were performed by a modification of methods
previously described.43,44 Membranes were slowly thawed and
diluted to a concentration of 0.4 mg of protein/mL for renal
and cerebral cortex and 0.7 mg of protein/mL for calf’s bulbis.
Assays were conducted in a total volume of 525 íL in
polypropylene tubes, and each tube contained 500 íL of
membrane suspension, 20 íL of radioligand, and 5 íL of drug.
Incubation was initiated by the addition of membrane and was
carried out for 45 min at 25 °C. Nonspecific binding was
defined in the presence of yohimbine (10 íM) in [3H]RX 821002
binding assays, either phentolamine (10 íM) or guanabenz (5
íM) in [3H]-p-aminoclonidine binding assays, and either
tolazoline (10 íM) or amiloride (10 íM) in [3H]idazoxan binding
assays. For each drug, six concentrations from 10-4 to 10-11
M were used in triplicate. Incubations were terminated by
vacuum filtration over Whatman GF/B glass fiber filters using
a cell harvester. The filters were washed three times with the
buffer, placed in scintillation vials, covered with 2 mL of
scintillation cocktail (Pico-Fluor, Packard Instrument), and
counted (Packard 2000 CA). Protein was assayed by a Bradford
method.
Binding results were analyzed by linear regression, and the
curves were obtained with Graph PAD program (Institute for
Scientific Information, Philadelphia, PA). Ki was calculated
with the Cheng-Prusoff equation.
Analytical Methods. Plasma glucose was determined
using a glucose analyzer (Beckman Inc., Fullerton, CA).
Plasma immunoreactive insulin (IRI) concentration was de-
termined with a radioimmunoassay kit (CEA, Gif-sur-Yvette,
France). The lower limit of the assay was 19.5 pmol/L with a
coefficient of variation within and between assays of 6%.
Statistics. Results of Tables 1-3 are expressed as a mean
( SEM. The significance of differences between means was
evaluated by one-way analysis of variance (ANOVA), and
differences were considered significant at p < 0.05.
Partition Coefficients. Log P of bases was calculated
according to Rekker’s method40 and from Hansch’s data bank.41
f(1,2,4-trisubstituted-piperazinyl) ) log P(piperazine) - (2f(H
neg) + f(H)) ) -1.50 - 1.124 ) -2.624. f(2-substituted-
imidazolinyl) ) log P(tolazoline or 2-benzylimidazoline) -
f(benzyl) ) 2.65 - 2.359 ) +0.291. Controlled via another
way: f(2-imidazolinyl) ) f(2-imidazolyl) + 2f(H) ) -0.080 +
0.364 ) +0.284 (j¢j ) 0.007). f(1,4-disubstituted-2-(4′,5′-
dihydro-1′H-imidazolyl-2′-yl)piperazine) ) -2.333.
The hydrophobic fragmental constants of the 1,4-substitu-
ents of piperazine were added to this last value.
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